| Demenz
Evidenzbasierte Leitlinie zu Diagnose und Therapie
Entwickelt durch das medizinische Wissensnetzwerk evidence.de
der Universität Witten/Herdecke Referenzen
Hinweise: Nach Möglichkeit wurden Links zu den zitierten Dokumenten respektive den Zusammenfassungen gelegt. Die Links werden erst bei einem Update der Leitlinie erneut überprüft. Sollten Sie Probleme mit „toten Links“ haben, teilen Sie uns dies bitte unter info@evidence.de mit. Oftmals reicht die im Link enthaltene Nummer (PMID), um bei Pubmed/Medline (http://www4.ncbi.nlm.nih.gov/PubMed) den gewünschten Artikel wieder aufzufinden.
Mit Ausnahme von Leitlinien und Büchern wurde den Referenzen eine Evidenzklasse zugeordnet.
[1] McKhann G, Drachman DA, Folstein M, Katzman R, Price DL, Stadlan EM. Clinical diagnosis of Alzheimer's disease — Report of the NINCDS-ADRDA Work Group under the auspices of
Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984. 34: 939-44.
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=661 0841
[2] Diagnostisches und statistisches Manual psychischer Störungen; DSM IV; 4. Auflage; Hogrefe Verlag, 1996
[3] McGlone J, Gupta S, Humphrey D, Oppenheimer S, Mirsen T, Evans DR. Screening for
early dementia using memory complaints from patients and relatives. Arch Neurol 1990. 47:1189-1193.
Evidenzklasse: III
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=224 1616
[4] Koss E, Patterson MB, Ownby R, Stuckey JC, Whitehouse PJ. Memory evaluation in Alzheimer's disease. Caregivers'appraisals and objective testing. Arch Neurol 1993. 50: 92-97.
Evidenzklasse: III
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=841 8807
[5] Feher EP, Larrabee GJ, Sudilovsky A, Crook 3rd TH. Memory
self-report in Alzheimer's disease and in age-associated memory impairment. J Geriatr Psychiatr Neurol 1994. 7: 58-65.
Evidenzklasse: III
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=819 2832
[6] Tobiansky R, Blizard R, Livingston G, Mann A. The Gospel Oak study stage IV: the clinical relevance of subjective memory impairment in older people. Psychol Med 1995. 25: 779-786.
Evidenzklasse: III
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=748 0455
[7] Teri L, Larson EB, Reifler BV. Behavioral disturbance in dementia of the Alzheimer's type. J Am Geriatr Soc 1988. 36: 1-6.
Evidenzklasse: III
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=333 5725
[8] Blacker D, Tanzi RE. The genetics of Alzheimer disease. Arch Neurol 1998. 55: 294-6.
Evidenzklasse: IV
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=952 0001
[9] Van Duijn CM, Clayton D, Chandra V. Familial aggregation of Alzheimer's disease and related disorders: a collaborative re-analysis of case-control studies. Int J Epidemiol 1991. 20: S13-20.
Evidenzklasse: III
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=183 3349
[10] Mortimer JA, van Duijn CM, Chandra V, Fratiglioni L, Graves AB, Heyman A, Jorm AF, Kokmen E, Kondo K, Rocca WA, et al, Head trauma as a risk factor for Alzheimer’s disease: a collaborative
re-analysis of case-control studies. EURODERM Risk Factors Research Group; Int. J. Epidemiol.; 1991. 20: S 28-35
Evidenzklasse: III
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=183 3351
[11] Fratiglioni L, Grut M, Forsell Y, Viitanen M, Grafstrom M, Holmen K, Ericsson K, Backman L, Ahlbom A, Winblad B, Prevalence of Alzheimer’s disease and other dementias in an elderly urban population: relationship with age, sex, and education; Neurology; 1991. 41(12): S 1886-92
Evidenzklasse: III
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=174 5343
[12] Zhang MY, Katzman R, Salmon D, Jin H, Cai GJ, Wang ZY, Qu GY, Grant I, Yu E, Levy P, et al, The prevalence of dementia and Alzheimer’s disease in Shanghai, China: impact of age, gender, and education, Ann. Neurol.; 1990. 27 (4): S 428 - 37
Evidenzklasse: III
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=235 3798
[13] Reding M, Haycox J, Blass J. Depression in patients referred to a dementia clinic. A three-year prospective study. Arch Neurol 1985. 42: 894-896.
Evidenzklasse: III
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=402 6634
[14] Reifler BV, Larson E, Teri L, Poulsen M. Dementia of the Alzheimer's type and depression. J Am Geriatr Soc 1986. 34: 855-859.
Evidenzklasse: III
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=378
2698
[15] Johnson JC, Kerse NM, Gottlieb G, Wanich C, Sullivan E, Chen K; Prospective versus retrospective methods of identifying patients with delir; J. Am. Geriatr. Soc.; 1992. 40 (4): S. 316-9
Evidenzklasse: III
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=155 6357
[16] Small GW, Rabins PV, Barry PP, Buckholtz NS, DeKosky ST, Ferris SH, et al. Diagnosis and treatment of Alzheimer's disease and related disorders. Consensus statement of the American
Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. JAMA 1997. 278: 1363-71.
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=934 3469
[17] Teri L, Logsdon RG, Peskind E, Raskind M, Weiner MF, Tractenberg RE, et al. Treatment of agitation in AD: a randomized, placebo-controlled clinical trial. Neurology 2000;55(9):1271-8.
Evidenzklasse: Ib
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=110 87767
[18] O'Brien, J.T. and C.G. Ballard, Drugs for Alzheimer's disease. BMJ, 2001. 323 (7305): 123-4.
Evidenzklasse: IV
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11463665
http://bmj.com/cgi/content/full/323/7305/123
[19] Cooper B, Bickel H, Schaufele M. The ability of general practitioners to detect dementia and cognitive impairment in their elderly patients: a study in Mannheim. Int J Geriatr Psychiatry 1992. 7: 591-598.
Evidenzklasse: III
Link:
[20] O'Connor DW, Fertig A, Grande MJ, Hyde JB, Perry JR, Roland MO, et al. Dementia in general practice: the practical consequences of a more positive approach to diagnosis. Br J Gen Pract 1993. 43: 185-188.
Evidenzklasse: III
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=834 7384
[21] Tekin, S., L. A. Fairbanks, et al. Activities of daily living in Alzheimer's disease: neuropsychiatric, cognitive, and medical illness influences. Am J Geriatr Psychiatry 2001. 9(1): 81-6.
Evidenzklasse: III
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=111 56757
[22] Folstein MF,
Folstein SE, McHugh PR. "Mini-mental state": a practical method of grading the cognitive state of patients for the clinician. J Psychiatr Res 1975. 12: 189-98.
Evidenzklasse: III
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1202204
[23] Stuss DT, Meiran N, Guzman A, Lafleche G, Willmer J. Do long tests yield a more accurate diagnosis of dementia than short tests? Arch Neurol 1996. 53: 1033-9.
Evidenzklasse: III
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=885 9066
[24] Sunderland T, Hill JL, Mellow AM, Lawlor BA, Gundersheimer J, Newhouse PA, et al. Clock drawing in Alzheimer's disease. A novel measure of dementia severity. J Am Geriatr Soc 1989. 37: 725-729.
Evidenzklasse: III
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=275
4157
[25] Huntzinger JA, Rosse RB, Schwartz BL, Ross LA, Deutsch SI. Clock drawing in the screening assessment of cognitive impairment in an ambulatory care setting: a preliminary report. Gen Hosp Psychiatry 1992. 14: 142-144.
Evidenzklasse: III
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=159 2251
[26] Pfeffer RI, Kurosaki TT, Harrah CH. Measurement of
functional activities in older adults in the community. J Gerontol 1982. 37: 323-9.
Evidenzklasse: III
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=706 9156
[27] Hershey LA, Jaffe DF, Greenough PG. Validation of cognitive and functional assessment instruments in vascular dementia. Int J Psychiatry Med 1987. 17:183-92.
Evidenzklasse: III
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=361 0484
[28] Larson EB, Reifler BV, Sumi SM, Canfield CG, Chinn NM. Diagnostic tests in the evaluation of dementia. A prospective study of 200 elderly outpatients. Arch Intern Med 1986. 146: 1917-1922.
Evidenzklasse: IV
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=376 7535
[29] Kasa M, Bierma TJ, Waterstraat Jr F, Corsaut M, Singh SP. Routine blood chemistry screen: a diagnostic aid for Alzheimer's disease. Neuroepidemiology 1989. 8: 254-261.
Evidenzklasse: III
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=281
2184
[30] Chui H, Zhang Q. Evaluation of dementia: a systematic study of the usefulness of the American Academy of Neurology's practice parameters. Neurology 1997. 49: 925-35.
Evidenzklasse: III
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=933 9669
[31] Foster GR, Scott DA, Payne S, The use of CT scanning in dementia – an systematic review; Int. Journ. Of technol. Assess. In Health Care, 1999. 15(2): 406-423
Evidenzklasse: Ia
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=105 07198
[32] Clarfield AM. Assessing dementia: the Canadian consensus. CMAJ; 1991. 144(suppl): 851-3.
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2007235
[33] Verhey FR, Jolles J, Ponds RW, Rozendaal N, Plugge LA, de Vet RC, et al. Diagnosing dementia: a comparison between a monodisciplinary and a multidisciplinary approach. J Neuropsychiatry Clin Neurosci 1993. 5(1): 78-85.
Evidenzklasse: III
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8428140
[34] O'Connor DW, Pollitt PA, Brook CPB, Reiss BB. The validity of informant histories in a community study of dementia. Int J Geriatr Psychiatry 1989. 4: 203-8.
Evidenzklasse: III
Link:
[35] Koss E, Patterson MB, Ownby R, Stuckey JC, Whitehouse PJ.
Memory evaluation in Alzheimer's disease. Caregivers'appraisals and objective testing. Arch Neurol 1993. 50: 92-97.
Evidenzklasse: III
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=841 8807
[36] Schulz R, O'Brien AT, Bookwala J, Fleissner K. Psychiatric and physical morbidity effects of dementia caregiving: prevalence, correlates, and causes. Gerontologist 1995. 35: 771-91.
Evidenzklasse: Ia
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8557205
[37] Cohen D. A primary care checklist for effective family management. Med Clin North Am 1994. 78: 795-809.
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8022230
[38] Drickamer MA, Lachs MS. Should patients with Alzheimer's disease be told their diagnosis? N Engl J Med 1992. 326: 947-51.
Evidenzklasse: IV
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1542346
[39] De Deyn PP, Rabheru K, Rasmussen A, Bocksberger JP, Dautzenberg PL, Eriksson S, et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology 1999;53(5):946-55.
Evidenzklasse: Ib
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=104 96251
[40] Lord TR, Garner JE. Effects of music on Alzheimer patients. Perceptual Motor Skills 1993. 76: 451-455.
Evidenzklasse: Ib
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8483655
[41] Tappen RM. The effect of skill training on functional abilities of nursing home residents
with dementia. Res Nurs Health 1994. 17: 159-165.
Evidenzklasse: Ib
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8184127
[42]
Rovner BW, Steele CD, Shmuely Y, Folstein MF. A randomized trial of dementia care in nursing homes. J Am Geriatr Soc1996. 44: 7-13.
Evidenzklasse: Ib
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=853 7594
[43] Beck CK, Shue VM. Interventions for treating disruptive behavior in demented elderly people. Nurs Clin North Am 1994. 29: 143-55.
Evidenzklasse: IV
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=812
1817
[44] Small GW, Rabins PV, Barry PP, Buckholtz NS, DeKosky ST, Ferris SH, et al. Diagnosis and treatment of Alzheimer's disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. JAMA 1997. 278: 1363-71.
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=934 3469
[45] Schneider LS, Pollock VE, Lyness SA. A meta-analysis of
controlled trials of neuroleptic treatment in dementia. J Am Geriatr Soc 1990. 38: 553-63.
Evidenzklasse: Ia
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=197 0586
[46] Finkel SI, Lyons JS, Anderson RL. A randomized, placebo-controlled trial of thiothixene in agitated, demented nursing home patients. Int J Geriatr Psychiatry 1995.10:129-36.
Evidenzklasse: Ib
Link:
[47] Katz IR, Jeste DV, Mintzer JE, Clyde C, Napolitano J, Brecher M. Comparison
of risperidone and placebo for psychosis and behavioraldisturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. J Clin Psychiatry 1999. 60(2): 107-15.
Evidenzklasse: Ib
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=100
84637
[48] Tariot PN. Treatment of strategies for agitation and psychosis indementia. J Clin Psychiatry 1996. 57(Suppl 14): 21-9.
Evidenzklasse: IV
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=902
4333
[49] Hallauer, J.F., Schons, M., Smala, A.Berger, K., Untersuchung von Krankheitskosten bei Patienten mit Alzheimer-Erkrankung in Deutschland. Gesundheitsökonomie & Qualitätsmanagement, 2000. 5: p. 73-79.
Evidenzklasse: III
[50]
Doody, R. S., J. C. Stevens, et al. Practice parameter: Management of dementia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology, 2001. 56 (9): 1154-66.
Evidenzklasse: Ia
Link:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11342679
http://www.neurology.org/cgi/content/full/56/9/1154
[51] Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind,
placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 1998. 50(1): 136-45.
Evidenzklasse: Ib
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9443470
[52] Rogers SL, Friedhoff LT. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study. Eur Neuropsychopharmacol 1998. 8: 67-75.
Evidenzklasse: Ib
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9452942
[53] Rösler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, Stählein HB, Hartman R, Gharabawi M, Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomised controlled
trial; BMJ, 1999. 318: 633-640.
Evidenzklasse: Ib
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10066203 http://www.bmj.com/cgi/content/full/318/7184/633
[54]
Anand, R., Gharabawi, G., and Enz, A., Efficacy and safety results of the early phase studies with Exelon(TM) (ENA-713) in Alzheimer's disease: An overview. Journal of Drug Development & Clinical Practice, 1996. 8(2): p. 109-116.
Evidenzklasse: Ib
[55] Corey-Bloom J, Anand R, Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine
tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer’s disease; Int. J. Geriatr. Psychopharmacol; 1998. 1: 55-65
Evidenzklasse: Ib
[56] Kanowski S, Herrmann WM, Stephan K, Wierich W, Horr R. Proof of efficacy of the ginkgo biloba special extract Egb 761 in outpatientssuffering from mild to moderate primary degenerative
dementia of the Alzheimer type or multi-infarct dementia. Pharmacopsychiatry.1996. 29(2): 47-56.
Evidenzklasse: Ib
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8741021
[57] LeBars PL, Katz MM, Berman N, Itil TM, Freedman AM, Schatzberg AF. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. JAMA 1997. 278: 1327-32.
Evidenzklasse: Ib
Link: http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=9343463
[58] Sano M, Ernesto C, Thomas RG, Klauber MA, Schafer K, Grundman M, et al. A controlled trial of selegiline, alpha-tocopherol or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Eng J Med 1997. 336: 1216-22.
Evidenzklasse: Ib
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=911 0909
[59] ICD 10: Die Erstellung erfolgte unter Verwendung der
Datenträger der amtlichen ICD-10-Fassung des Deutschen Instituts für medizinische Dokumentation und Information (DIMDI). Für Band I: Veröffentlicht durch die Weltgesundheitsorganisation unter dem Titel International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, Volume 1, 1992 (c) World Health Organization 1992 (Volume 1)
[60] Jörg J. Neurologische Therapie. Springer-Verlag Berlin Heidelberg 1997. S. 429 - 430
[61] Reisberg, B., et al., The Alzheimer's disease activities of daily living international scale (ADL-IS). Int Psychogeriatr, 2001. 13(2): 163-81.
Evidenzklasse: III
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11495392
[62] Antiplatelet Trialists`Collaboration. Collaborative overview of randomised trials of antiplatelet therapy I:
prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994. 308: 81-106.
Evidenzklasse: Ia
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=829 8418
[63] SALT Collaborative Group. Swedish aspirin low-dose trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet 1991. 338: 1345-1349
Evidenzklasse: Ib
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=168 2734
[64] Flicker L, Grimley Evans J. Piracetam for dementia or cognitive impairment (Cochrane Review). In: The Cochrane Library, Issue 3, 2003. Oxford: Update Software.
Evidenzklasse: Ia
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11405971
http://www.update-software.com/abstracts/ab001011.htm
[65] López-Arrieta, Birks J. Nimodipine for primary degenerative, mixed and vascular dementia (Cochrane Review). In: The Cochrane Library, Issue 3, 2003. Oxford: Update Software.
Evidenzklasse: Ia
Link:
[66] Pantoni, L., Bianchi, C., Beneke, M., Inzitari, D., Wallin, A.Erkinjuntti, T., The Scandinavian Multi-Infarct Dementia Trial: a double-blind, placebo-controlled trial on nimodipine in multi-infarct dementia. J Neurol Sci, 2000. 175(2): p. 116-23.
Evidenzklasse: Ib
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=108 31772
[67] Winblad, B., Poritis, N. Memantine in severe dementia: results of the 9M-Best Study (benefit and efficacy in
severely demented patients during treatment with memantine. Int J Geriatr Psychiatry 1999. 14(2): 135-46.
Evidenzklasse: Ib
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10885864
[68] Demers, L., M. Oremus, et al. Review of outcome measurement instruments in Alzheimer's disease drug trials: psychometric properties of functional and quality of life scales. J Geriatr Psychiatry Neuro, 2000. 13(4): 170-80.
Evidenzklasse: IV
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11128057
[69] Raskind, M. A., E. R. Peskind, et al. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology, 2000. 54(12): 2261-8.
Evidenzklasse: Ib
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10881250
[70] Tariot, P. N., P. R. Solomon, et al. A 5-month,
randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology, 2000. 54(12): 2269-76.
Evidenzklasse: Ib
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10881251
[71] Williams PS, Rands G, Orrel M, Spector A. Aspirin for vascular dementia (Cochrane Review). In: The Cochrane Library, Issue 3, 2003. Oxford: Update Software.
Evidenzklasse: Ia
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11034710
[72] Birks JS, Melzer D, Beppu H. Donepezil for mild and moderate Alzheimer's disease (Cochrane Review). In: The Cochrane Library, Issue 3, 2003. Oxford: Update Software.
Evidenzklasse: Ia
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11034704
[73] Olin J, Schneider L. Galantamine for Alzheimer's disease (Cochrane Review). In: The Cochrane Library, Issue 3, 2003. Oxford: Update Software.
Evidenzklasse: Ia
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12137632
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11279727
http://www.update-software.com/abstracts/ab001747.htm
[74] Birks J, Grimley Evans J, Iakovidou V, Tsolaki M. Rivastigmine for Alzheimer's disease (Cochrane Review). In: The Cochrane Library, Issue 3, 2003. Oxford: Update Software.
Evidenzklasse: Ia
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11034705
[75] Rizzo, M., D. V. McGehee, et al. Simulated car crashes at intersections in drivers with Alzheimer disease. Alzheimer Dis Assoc Disord. 2001. 15(1): 10-20.
Evidenzklasse: III
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11236820
[76] Viitanen, M., K. Johansson, et al. Alzheimer changes are common in aged drivers killed in single car crashes and at intersections. Forensic Sci Int.1998. 96(2-3): 115-27.
Evidenzklasse: III
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9854829
[77] Drachman, D. A. and J. M. Swearer. Driving and Alzheimer's disease: the risk of crashes. Neurology, 1993. 43(12): 2448-56.
Evidenzklasse: Ib
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8255438
[78] Lundberg, C., K. Johansson, et al. Dementia and driving: an attempt at consensus. Alzheimer
Dis Assoc Disord, 1997. 11(1): 28-37.
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9071442
[79] Knopman, D. S., S. T. DeKosky, et
al. Practice parameter: Diagnosis of dementia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology.Neurology, 2001. 56(9): 1143-53.
Evidenzklasse: Ia
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11342678
http://www.neurology.org/cgi/content/full/56/9/1143
http://www.neurology.org/cgi/content/abstract/56/9/1143
[80] Petersen, R. C., J. C. Stevens, et al. Practice parameter: Early detection of dementia: Mild cognitive impairment (an evidence-based review): Report of the Quality Standards
Subcommittee of the American Academy of Neurology.Neurology, 2001. 56(9): 1133-42.
Evidenzklasse: Ia
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11342677
http://www.neurology.org/cgi/content/full/56/9/1133
http://www.neurology.org/cgi/content/abstract/56/9/1133
[81] Katzman R, Lasker B, Bernstein N. Advances in the diagnosis of dementia: accuracy of diagnosis and consequences of misdiagnosis of disorders causing dementia. In: Terry RD, editor. Aging and the brain. New York: Raven Press; 1988. 17-62. Copyright 1988, Raven Press.
Evidenzklasse:
Link:
[82] Ballard, C. and M. Walker, Neuropsychiatric aspects of Alzheimer's disease. Curr Psychiatry Rep, 1999. 1(1): 49-60.
Evidenzklasse: IV
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11122905
[83] Erkinjuntti, T., T. Sawada, and P.J. Whitehouse, The Osaka Conference on Vascular Dementia 1998. Alzheimer Dis Assoc Disord, 1999. 13 Suppl 3: S1-3.
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10609674
[84] Mayeux, R. and M. Sano, Treatment of Alzheimer's disease. N Engl J Med, 1999. 341(22): 1670-9.
Evidenzklasse: IV
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10572156
[85] Reisberg, B., et al., Clinical global measures of dementia. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Alzheimer Dis Assoc Disord, 1997. 11(Suppl 3): 8-18.
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9305508
[86] Rosler, M., et al., Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. Bmj, 1999. 318: 633-8.
Evidenzklasse: Ib
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10066203
http://www.bmj.com/cgi/content/full/318/7184/633
[87] Skoog, I., Status of risk factors for vascular dementia. Neuroepidemiology, 1998. 17(1): 2-9.
Evidenzklasse: IV
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9549718
[88] Williams, R., Optimal dosing with risperidone: updated recommendations. J Clin Psychiatry, 2001. 62(4): 282-9.
Evidenzklasse: IV
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11379843
[89] Swartz, M., et al., Treating depression in Alzheimer's disease: integration of differing guidelines. Int Psychogeriatr, 2000. 12(3): 353-8.
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11081955
[90] Thase, M.E., et al., Treatment of men with major depression: a comparison of sequential cohorts treated with either cognitive-behavioral therapy or newer generation antidepressants. J Clin Psychiatry, 2000. 61(7): 466-72.
Evidenzklasse: Ib
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10937603
[91] van Eijk, M.E.C., et al., Reducing prescribing of highly anticholinergic antidepressants for elderly people: randomised trial of group versus individual academic. BMJ, 2001. 322: 654.
Evidenzklasse: Ib
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=112 50852
[92] Wilkinson, D. and J. Murray, Galantamine: a randomized, double-blind, dose comparison in patients with Alzheimer's disease. Int J Geriatr Psychiatry, 2001. 16(9): 852-7.
Evidenzklasse: Ib
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11571763
[93] van Dongen, M.C., et al., The efficacy of ginkgo for elderly people with dementia and age- associated memory impairment: new results of a randomized clinical trial. J Am Geriatr Soc, 2000. 48(10): 1183-94.
Evidenzklasse: Ib
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11037003
[94] Folstein MF, Folstein SE, McHugh PR. "Mini Mental State"- A practical method
for grading the cognitivestate of patients for the clinician. Journal of Psychiatric Research 1975;12:189-198.
Evidenzklasse: III
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1202204
[95] Higgins JPT, Flicker L. Lecithin for dementia and cognitive impairment (Cochrane Review). In: The Cochrane Library, Issue 3, 2003. Oxford: Update Software.
Evidenzklasse: Ia
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11034695
[96] Scott HD, Laake K. Statins for the prevention of Alzheimer's disease (Cochrane Review). In: The Cochrane Library, Issue 3, 2003. Oxford: Update Software.
Evidenzklasse: Ia
Link: http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=11687176 http://www.update-software.com/abstracts/ab003160.htm
[97] Birks J, Flicker L. Selegiline for Alzheimer's disease (Cochrane Review). In: The Cochrane
Library, Issue 3, 2003. Oxford: Update Software.
Evidenzklasse: Ia
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12535396
[98] Birks J, Grimley Evans J, Van Dongen M. Ginkgo biloba for dementia and cognitive impairment (Cochrane Review). In: The Cochrane Library, Issue 3, 2003. Oxford: Update Software.
Evidenzklasse: Ia
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=125
19586
[99] Verghese, J., et al., Leisure activities and the risk of dementia in the elderly. N Engl J Med, 2003. 348(25): p. 2508-16.
Evidenzklasse: III
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=128
15136
[100] Schwabe, U., Antidementiva, in Arzneiverordnungsreport 2001, U. Schwabe und D. Paffrath, Editoren. 2001, Springer: Berlin. S.151-162.
[101] Thompson, T.L. II, Filley C.M. et al., Lack of efficacy of hydergine in patients with
Alzheimer's disease. N Engl J Med, 1990. 323 (7): S. 445-8.
Evidenzklasse: Ib
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2082953
[102] Olin J, Schneider L, Novit A, Luczak S. Hydergine for dementia (Cochrane Review). In: The Cochrane Library, Issue 3, 2003. Oxford: Update Software.
Evidenzklasse: Ia
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11405961
http://www.update-software.com/abstracts/ab000359.htm
[103] Solomon PR et al., Ginkgo for memory enhancement. A randomized controlled trial. Jama 2002,288: 835-840
Evidenzklasse: Ib
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12186600
[104] Arzneimittelkommission der deutschen Ärzteschaft, Blutungen unter der Gabe von
Ginkgo-biloba-Extrakten. Cave Kombination mit Gerinnungshemmern, Deutsches Ärzteblatt 2002, Jahrgang 99, Heft 33: A2214
Evidenzklasse: IV
Link: http://www.aerzteblatt.de/v4/archiv/artikel.asp?id=32658
[105]
Zoller B, Hock C, Kull HU. Rational therapy of Alzheimer dementia based on current clinical studies. Schweiz Rundsch Med Prax 2001, 90 (19), 827-834.
Evidenzklasse: Ia
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=126 91498
[106] Oken BS, Storzbach DM, Kaye JA. The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease. Arch Neurol 1998;55(11):1409-15.
Evidenzklasse: Ia
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9823823
[107] Ernst E, Pittler MH. Ginkgo biliba for dementia A systematic review of double-blind, placebo controlled trials. Clin Drug Invest 1999;17(4):301-8.
Evidenzklasse: Ia
Link:
[108] Le Bars PL, Kieser M, Itil KZ. A 26-week analysis of a double-blind,
placebo-controlled trial of the ginkgo biloba extract EGb 761 in dementia. Dement Geriatr Cogn Disord 2000; 11(4):230-7
Evidenzklasse: Ib
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10867450 http://www.online.karger.com/library/karger/renderer/dataset.exe?jcode=DEM&action=render&renderty pe=fulltext&uid=DEM.dem11230
[109] Le Bars PL, Velasco FM, Ferguson JM, Dessain EC, Kieser M, Hoerr R. Influence of the severity of cognitive impairment on the effect of the Ginkgo biloba extract EGb 761 in Alzheimer's disease. Neuropsychobiology 2002;45(1):19-26.
Evidenzklasse: Ib
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11803237
[110] Rowin J, Lewis SL. Spontaneous bilateral subdural hematomas associated with chronic Ginkgo biloba ingestion. Neurology 1996;46(6):1775-6.
Evidenzklasse: IV
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8649594
[111] Vale S. Subarachnoid haemorrhage associated with Ginkgo biloba. Lancet 1998;352(9121):36
Evidenzklasse: IV
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9800751
[112] Izzo AA, Ernst E. Interactions between herbal
medicines and prescribed drugs: a systematic review. Drugs 2001;61(15):2163-75.
Evidenzklasse: Ia
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11772128
[113] Patterson, C. J., et al., The recognition, assessment and management of dementing disorders: conclusions from the Canadian Consensus Conference on Dementia. CMAJ, 1999. 160(12 Suppl): p. S1-15.
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=104
10645
[114] Eccles M, Clarke J, Livingston M, Freemantle N, Mason J, North of England evidence based guidelines development project: guideline for the primary care management of dementia; BMJ; 1998; 317:802-808, (19 Sept.)
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=974 0574
[115] Recognition and Initial Assessment of Alzheimer’s Disease and Related Dementias; Clinical Practice Guideline No. 19; AHCPR Public. No. 97-0702: Nov. 1996
Link: http://hstat.nlm.nih.gov/hq/Hquest/db/3101/screen/DocTitle/odas/1/s/59126
[116] Sainsbury R, Collins Ch., Duff G, Harrison J, Haydon R, Wilkinson T, Guidelines for the Support and Management of People
with Dementia Guideline Team, New Zealand Guideline Group; New Zealand, 1998-2000; ENIGMA Publishing LTD
Link: http://www.nzgg.org.nz/library/gl_complete/dementia/index.cfm
[117] AKDÄ: Demenz.
Arzneiverordnung in der Praxis (AVP). Therapieempfehlungen der Arzneimittelkommission der deutschen Ärzteschaft, Vol. 2. 2000, Köln.
Link: http://www.akdae.de/35/10Hefte/91_Demenz_2000_2Auflage_k.pdf
Volltext: http://www.akdae.de/35/10Hefte/91_Demenz_2000_2Auflage.pdf
[118] Deutsche Gesellschaft für Psychiatrie und Psychotherapie (DGPPN): Behandlungsleitlinie Demenz. Praxisleitlinien in Psychiatrie und Psychotherapie,
Ed. W. Gaebel and P. Falkai. 2000, Darmstadt: Steinkopff Verlag.
Link:
[119] Bund Deutscher Allgemeinmediziner (BDA): Manual Demenz, 2. Auflage 1999 Herausgeber: BDA, Emsdetten.
Link:
[120] Bund Deutscher Allgemeinmediziner (BDA): Case-Managment
Demenz, 1. Auflage 2000. Herausgeber: BDA, Emsdetten.
Link:
[121] National Institute for Clinical Excellence (NHS): Guidance on the use of donepezil, rivastigmine, and galantamine for the treatment of alzheimer´s disease. 2001, National Institute for Clinical Excellence.
Link:
[122] Scottish Intercollegiate Guidlines Network (SIGN): Interventions in the management of behavioural and psychological aspects of dementia. 1998.
Link: http://www.sign.ac.uk/guidelines/published/index.html
http://www.sign.ac.uk/pdf/sign22.pdf
[123] CPMP. Note for guidance on medicinal products in the Treatment of Alzheimer´s Disease. Committee for Proprietary Medicinal
Products 1997.
Link:
[124] Howard R, Ballard C, O'Brien J, Burns A. Guidelines for the management of agitation in dementia. Int J Geriatr Psychiatry 2001;16(7):714-7.
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11466751
[125] Cummings JL, Frank JC, Cherry D, Kohatsu ND, Kemp B, Hewett L, et al. Guidelines for managing Alzheimer's disease: part I. Assessment. Am Fam Physician 2002;65(11):2263-72.
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12074525
[126] Cummings JL, Frank JC, Cherry D, Kohatsu ND, Kemp B, Hewett L, et al. Guidelines for managing Alzheimer's disease: Part II. Treatment. Am Fam Physician 2002;65(12):2525-34.
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12086242
[127] NZGC. Guidelines for the Use of Acetylcholinesterase Inhibitor Drugs in the Treatment of People With Alzheimer's Disease. 2000.
Link: http://www.nzgg.org.nz/library/gl_complete/Acetylcholinesterase/index.cfm#contents
[128] Brotons M, Koger S. Music Therapy and Dementias: A Review of Literature. Journal of Music Therapy 1997;XXXIV(4):204-245.
Evidenzklasse: IV
Link:
[129] Koger S, Brotons M. Music therapy for dementia symptoms (Cochrane Protocol). Cochrane Database
Syst Rev 2000;3.
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=109 08486
[130] Vink AC, Bruinsma
MS, Scholten R. Music therapy in the care of people with dementia (Protocol for a Cochrane Review). In: The Cochrane Library. Oxford: Update Software; 2003(3).
Evidenzklasse: Ia
Link:
[131] Clare L, Woods RT, Moniz Cook ED, Orrell M, Spector A. Cognitive rehabilitation interventions to improve memory functioning in early-stage Alzheimer's disease and vascular
dementia (Protocol for a Cochrane Review). In: The Cochrane Library. Oxford: Update Software; 2003(3).
Link: www.update-software.com/cochrane
[132] McShane R, Keene J, Gedling K, Fairburn C, Jacoby R, Hope T. Do neuroleptic
drugs hasten cognitive decline in dementia? Prospective study with necropsy follow up. Bmj 1997;314(7076):266-270.
Evidenzklasse: III
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=902 2490
Volltext: http://bmj.com/cgi/content/full/314/7076/266
[133] McKeith I, Fairbairn A, Perry R, Thompson P, Perry E. Neuroleptic sensitivity in patients with senile
dementia of Lewy body type. Bmj 1992;305(6855):673-8.
Evidenzklasse: III
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=135 6550
[134] Trinh NH, Hoblyn J, Mohanty S, Yaffe K. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. Jama 2003;289(2):210-6.
Evidenzklasse: Ia
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=125
17232
[135] Leucht S, Wahlbeck K, Hamann J, Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003;361(9369):1581-9.
Evidenzklasse: Ia
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=127 47876
[136] Street JS, Clark WS, Gannon KS, Cummings JL, Bymaster FP, Tamura RN, et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care
facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Arch Gen Psychiatry 2000;57(10):968-76.
Evidenzklasse: Ib
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=110 15815
[137] Rietbrock N, Staib AH, Loew D. Klinische Pharmakologie - Arzneitherapie. Darmstadt: Steinkopff Verlag; 2001
[138] US Department of Health and Human Services. Agency for Health Care Policy and Research. Acute Pain Management: operative or medical procedures
and trauma. Rockville (MD): The Agency; 1993. Clinical Practice Guideline No.1. AHCPR Publication No.92-0023. p.107.
Link: http://hstat.nlm.nih.gov/hq/Hquest/db/local.arahcpr.arclin.apmc/screen/TocDisplay/s/34949/action/Toc
[139] McGrath AM, Jackson GA. Survey of neuroleptic prescribing in residents of nursing homes in Glasgow. Bmj 1996;312(7031):611-2.
Evidenzklasse: III
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=859
5335
Volltext: http://bmj.com/cgi/content/full/312/7031/611
[140] Manktelow B, Gillies C, Potter JF. Interventions in the management of
serum lipids for preventing stroke recurrence (Cochrane Review). Cochrane Database Syst Rev 2003(3).
Evidenzklasse: Ia
Link: http://www.update-software.com/Cochrane/default.HTM
[141] Reisberg B, Doody R,
Stoffler A, Schmitt F, Ferris S, Mobius HJ. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003;348(14):1333-41.
Evidenzklasse: Ib
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=126 72860
[142] Reisberg B, Stoffler A, Ferris SH. Memantine in moderately severe to severe Alzheimer´s disease: results of a placebo-controlled 6 month trial. Neurobiol. Aging 2000;21:S275.
Evidenzklasse: Ib
Link:
[143] Pantev M, Ritter R, Görtelmeyer R. Clinical
and behavioral evaluation in long-term care patients with mild to moderate dementia under Memantine treatment. Z. Geronto-psychol-psychiatrie 1993;6(2):103-117.
Evidenzklasse: Ib
[144] Orgogozo JM, Rigaud AS, Stoffler A, Mobius HJ, Forette F. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial
(MMM 300). Stroke 2002;33(7):1834-9.
Evidenzklasse: Ib
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12105362
[145] Areosa
Sastre A, Sherriff F. Memantine for dementia (Cochrane Review). In: The Cochrane Library. Oxford: Update Software; 2005; 3.
Evidenzklasse: Ia
Link: http://www.update-software.com/Cochrane/default.HTM
[146] van
Dongen M, Rossum E, Kessels A, Sielhorst H, Knipschild P. Ginkgo for elderly people with dementia and age-associated memory impairment: a randomized clinical trial. J Clin Epidemiol 2003;56(4):367-76.
Evidenzklasse: Ib
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=127
67414
[147] Kivipelto, Miia, et al., Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ, 2001. 322(7300): p. 1447-1451.
Evidenzklasse: III
Link: http://bmj.com/cgi/content/abstract/322/7300/1447
[148] Wilcock, G. K., et al., The effect of selegiline in the treatment of people with Alzheimer's disease: a meta-analysis of published trials. Int J Geriatr Psychiatry, 2002. 17(2): p. 175-83.
Evidenzklasse: Ia
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=118 13282
[149] Laake, K. and Oeksengaard, A.R., D-cycloserine for Alzheimer's disease (Cochrane Review), in The Cochrane Library, 2003(3), Update Software: Oxford.
Evidenzklasse: Ia
Link: http://www.update-software.com/Cochrane/default.HTM
[150] Rodriguez-Martin, J. L., Qizilbash, N., and Lopez-Arrieta, J. M., Thiamine for Alzheimer's disease (Cochrane Review). Cochrane Database Syst Rev, 2003(3).
Evidenzklasse: Ia
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11405995
http://www.update-software.com/abstracts/ab001498.htm
[151] Malouf, R. and Areosa Sastre, A., Folic Acid with or without vitamin B12 for cognition and dementia. (Protocol for a Cochrane Review), in The Cochrane Library. 2003(3), Update Software: Oxford.
Evidenzklasse: III
Link: http://www.update-software.com/Cochrane/default.HTM
[152] Aisen, P. S., et al., A pilot study of vitamins to lower plasma homocysteine levels in Alzheimer disease. Am J Geriatr Psychiatry, 2003. 11(2): p. 246-9.
Evidenzklasse: IIa
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=126 11755
[153] Shepherd, J., et al., Pravastatin in elderly
individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet, 2002. 360(9346): p. 1623-30.
Evidenzklasse: Ib
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=124 57784
[154] Clarke, R., et al., Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch Neurol, 1998. 55(11): p. 1449-55.
Evidenzklasse: III
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=982
3829
[155] Shaw, D. M., et al., Folate and amine metabolites in senile dementia: a combined trial and biochemical study. Psychol Med, 1971. 1(2): p. 166-71.
Evidenzklasse: III
Link:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=514 8767
[156] VITAL Trial Collaborative Group, Effect of vitamins and aspirin on markers of platelet activation, oxidative stress and homocysteine in people at high risk of dementia. J Intern Med, 2003. 254(1):
p. 67-75.
Evidenzklasse: Ib
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=128 23643
[157] Jick, H., et al., Statins and the risk of dementia. Lancet, 2000. 356(9242): p. 1627-31.
Evidenzklasse: III
Link: http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=11089820
[158] Crisby, M., Carlson, L. A., and Winblad, B., Statins in the prevention and treatment of Alzheimer disease. Alzheimer Dis Assoc Disord, 2002. 16(3): p. 131-6.
Evidenzklasse: IV
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=122
18642
[159] Austen, B., Christodoulou, G., and Terry, J. E., Relation between cholesterol levels, statins and Alzheimer's disease in the human population. J Nutr Health Aging, 2002. 6(6): p. 377-82.
Evidenzklasse: IV
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=124 59888
[160] Manktelow, B. , Gillies, C., and Potter, J.F., Interventions in the management of serum lipids for preventing stroke recurrence (Cochrane Review). Cochrane Database Syst Rev, 2003(3).
Evidenzklasse: Ia
Link: http://www.update-software.com/Cochrane/default.HTM
[161] Law, M. R., Wald, N. J., and Rudnicka, A. R., Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart
disease, and stroke: systematic review and meta-analysis. Bmj, 2003. 326(7404): p. 1423.
Evidenzklasse: Ia
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=128 29554
[162] Wald, N. J. and Law, M. R., A strategy to reduce cardiovascular disease by more than 80%. Bmj, 2003. 326(7404): p. 1419.
Evidenzklasse: Ia
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=128
29553
[163] Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. Homocysteine Lowering Trialists' Collaboration. Bmj, 1998. 316(7135): p. 894-8.
Evidenzklasse: Ia
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=956 9395
[164] Wald, D. S., Law, M., and Morris, J. K., Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. Bmj, 2002. 325(7374): p. 1202.
Evidenzklasse: Ia
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=124 46535
[165] Seshadri, S., et al., Plasma homocysteine as a risk
factor for dementia and Alzheimer's disease. N Engl J Med, 2002. 346(7): p. 476-83.
Evidenzklasse: III
Link: http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=11844848
[166] Shumaker, S. A., et al., Estrogen Plus Progestin and the Incidence of Dementia and Mild Cognitive Impairment in Postmenopausal Women: The Women's Health Initiative Memory Study: A Randomized Controlled Trial. Jama, 2003. 289(20): p. 2651-62.
Evidenzklasse: Ib
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=127 71112
[167] Ott, A., et al., Smoking and risk of dementia and Alzheimer's disease in a population- based cohort study: the Rotterdam Study. Lancet, 1998. 351(9119): p. 1840-3.
Evidenzklasse: III
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=9652667&dopt=Cit ation
[168] Ruitenberg, A., et al., Blood Pressure and the Risk of
Dementia: Results from the Gothenburg H-70 Study and the Rotterdam Study. Neurology, 1999. 52(6 (Suppl 2)): p. A297.
Evidenzklasse: III
[169] Ruitenberg, A., et al., Blood pressure and risk of dementia: results from the Rotterdam study and the Gothenburg H-70 Study. Dement Geriatr Cogn Disord, 2001. 12(1): p. 33-9.
Evidenzklasse: III
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=111 25239
[170] Ruitenberg, A., et al., Alcohol consumption and risk of
dementia: the Rotterdam Study. Lancet, 2002. 359(9303): p. 281-6.
Evidenzklasse: III
Link: http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=11830193
[171] Fratiglioni, L., et al., Risk factors for late-onset Alzheimer's disease: a population-based, case-control study. Ann Neurol, 1993. 33(3): p. 258-66.
Evidenzklasse: III
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=849
8809
[172] Saunders, P. A., et al., Heavy drinking as a risk factor for depression and dementia in elderly men. Findings from the Liverpool longitudinal community study. Br J Psychiatry, 1991. 159: p. 213-6.
Evidenzklasse: III
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=177 3236
[173] Wooltorton, E., Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials. CMAJ, 2002. 167(11): p. 1269-70.
Evidenzklasse: IV
Link:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=124 51085
[174] Koro, C. E., Fedder, D. O., L'Italien, G. J., Weiss, S.
S., Magder, L. S., Kreyenbuhl, J., Revicki, D. A.Buchanan, R. W., Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. Bmj, 2002. 325(7358): p. 243.
Evidenzklasse: III
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=121
53919
[175] Katsunuma, H., Shimizu, T., Ogawa, K., Kubo, H., Ishida, H.Yoshihama, A., Treatment of insomnia by concomitant therapy with Zopiclone and Aniracetam in patients with cerebral infarction, cerebroatrophy, Alzheimer's disease and Parkinson's disease. Psychiatry Clin Neurosci, 1998. 52(2): p. 198-200.
Evidenzklasse: IV
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=962 8149
[176] Cummings, J. L., Street, J., Masterman, D.Clark, W. S.,
Efficacy of olanzapine in the treatment of psychosis in dementia with lewy bodies. Dement Geriatr Cogn Disord, 2002. 13(2): p. 67-73.
Evidenzklasse: Ib
Link:
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=11844887
[177] Medizinisches Wissensnetzwerk evidence.de der Universität Witten/Herdecke. Leitlinie Diagnose, Therapie und Versorgung bei Demenz Version 3/2001 und Version 12/2001.
www.evidence.de
[178] Entwurf der DEGAM-Leitlinie „Demenz“, Leitlinienautoren: Peter Mand, Martin Butzlaff, Horst Christian Vollmar, Deutsche Gesellschaft für Allgemeinmedizin. 2003. Unveröffentlicht.
[179] McGrath, A. M. and Jackson, G. A., Survey of neuroleptic prescribing in residents of nursing homes in Glasgow. Bmj, 1996. 312(7031): p. 611-2.
Evidenzklasse: III
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=859 5335
http://bmj.com/cgi/content/full/312/7031/611
[180] Steele, C., Rovner, B., Chase, G. A.Folstein, M., Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. Am J Psychiatry, 1990. 147(8): p. 1049-51.
Evidenzklasse: III
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=237 5439
[181] Haupt, M. and Kurz, A., Predictors of nursing home placement in patients with alzheimer´s disease. Int J Geriat Psychiatry, 1993. 8: p. 741-6.
Evidenzklasse: III
[182] Kurz, A. and Jendroska, K., Therapie und Prävention, in Demenzen
Grundlagen und Klinik, K. Beyreuther, et al., Editors. 2002, Thieme Verlag: Suttgart, New York. p. 187-210.
[183] Wilcock, G., Mobius, H. J.Stoffler, A., A double-blind, placebo-controlled multicentre study
of memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychopharmacol, 2002. 17(6): p. 297-305.
Evidenzklasse: Ib
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=124 09683
[184] McKeith, I., Del Ser, T., Spano, P., Emre, M., Wesnes, K., Anand, R., Cicin-Sain, A., Ferrara, R.Spiegel, R., Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet, 2000. 356(9247): p. 2031-6.
Evidenzklasse: Ib
Link: http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=11145488
[185] Kurz A. Klinik. In: Beyreuther K, Einhäup KM, Förstl H, Kurz A, editors. Demenzen.
Grundlagen und Klinik. Suttgart, New York: Thieme Verlag; 2002. p. 187-210.
[186] Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. Jama 2003;289(21):2819-26.
Evidenzklasse: Ib
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=127 83912
[187] Zandi PP, Anthony JC, Hayden KM, Mehta K, Mayer L,
Breitner JC. Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County Study. Neurology 2002;59(6):880-6.
Evidenzklasse: III
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=122 97571
[188 ] Poirier J. Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action. Int J Clin Pract Suppl 2002(127):6-19.
Evidenzklasse: IV
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12139368
[189] Farlow M. A clinical overview of cholinesterase inhibitors in Alzheimer's disease. Int Psychogeriatr 2002;14(Suppl 1):93-126.
Evidenzklasse: IV
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12636182
[190] Hogan DB, Patterson C. Progress in clinical neurosciences: Treatment of Alzheimer's disease and other dementias - review and comparison of the cholinesterase inhibitors. Can J Neurol Sci 2002;29(4):306-14.
Evidenzklasse: Ia
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12463485
[191] Auriacombe S, Pere JJ, Loria-Kanza Y, Vellas B. Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil. Curr Med Res Opin 2002;18(3):129-38.
Evidenzklasse: III
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12094822
[192] Wolfson C, Oremus M, Shukla V, Momoli F, Demers L,
Perrault A, et al. Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost-effectiveness. Clin Ther 2002;24(6):862-86; discussion 837.
Evidenzklasse: Ia
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12117079
[193] Cummings JL. Use of cholinesterase inhibitors in clinical practice: Evidence-based recommendations. American Journal of Geriatric Psychiatry 2003;11(2):131-145.
Evidenzklasse: Ia
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=126 11743
[194] Finucane TE. Cholinesterase inhibitors for Alzheimer disease. Jama 2003;289(18):2359; author reply 2360-1.
Evidenzklasse: IV
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=127 46353
[195] Fachbereich Evidenz-basierte Medizin, Ziegler S, Arndt
C, Windeler J. Donepezil, Rivastigmin und Galantamin in der Therapie der Demenz vom Alzheimer-Typ: Medizinischer Dienst der Spitzenverbände der Krankenkassen e.V.; 2002 13.03.2002.
[196] Sha MC, Callahan CM. The efficacy of pentoxifylline in the treatment of vascular dementia: a systematic review. Alzheimer Dis Assoc Disord 2003;17(1):46-54.
Evidenzklasse: Ia
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=126 21319
[197] Adler G, Kuskowski M. Driving Cessation in Older Men
With Dementia. Alzheimer Disease & Associated Disorders April/June 2003;17(2):68-71.
Evidenzklasse: III
[198] Bickel, H., [Dementia syndrome and Alzheimer disease: an assessment of morbidity and annual incidence in Germany]. Gesundheitswesen, 2000. 62(4): p. 211-8.
Evidenzklasse: III
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=108 44818
[199] Bickel, H., [Dementia in advanced age: estimating
incidence and health care costs]. Z Gerontol Geriatr, 2001. 34(2): p. 108-15.
Evidenzklasse: III
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=113 93002
[200] Kessler, J., Calabrese, P., Kalbe, E.Berger, F., DemTect: A new screening method to support diagnosis of dementia. Psycho, 2000. 26(6): p. 343-347.
Evidenzklasse: III
[201] Perneczky, R., The appropriateness of short cognitive tests for the identification of mild cognitive
impairment and mild dementia. Aktuelle Neurologie, 2003. 30(3): p. 114-117.
Evidenzklasse: III
[202] Ihl, R., Gross-Kapanke, B., Lahrem, P., Brinkmeyer, J., Fischer, S., Gaab, N.Kaupmannsennecke, C., Entwicklung und Validierung eines Tests zur Früherkennung der Demenz mit Depressionsabgrenzung (TFDD). Fortschritte der Neurologie und Psychiatrie, 2000. 68.
Evidenzklasse: III
[203] Vermeer, S. E., Prins, N. D., den Heijer, T., Hofman, A., Koudstaal, P. J.Breteler, M. M., Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med, 2003. 348(13): p. 1215-22.
Evidenzklasse: III
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=126 60385
[204] Moretti, R., Torre, P., Antonello, R. M.Cazzato, G.,
Rivastigmine in subcortical vascular dementia: a comparison trial on efficacy and tolerability for 12 months follow-up. Eur J Neurol, 2001. 8(4): p. 361-2.
Evidenzklasse: IV
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11422435
[205] Tariot, P. N., Cummings, J. L., Katz, I. R., Mintzer, J., Perdomo, C. A., Schwam, E. M.Whalen, E., A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. J Am Geriatr Soc, 2001. 49(12): p. 1590-9.
Evidenzklasse: Ib
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11843990
[206] O'Brien JT, Erkinjuntti T, Reisberg B, Roman G, Sawada T, Pantoni L, et al. Vascular
cognitive impairment. Lancet Neurol 2003;2(2):89-98.
Evidenzklasse: IV
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=128 49265
[207] Malouf R, Birks J. Donepezil for vascular cognitive impairment (Review). In: The Cochrane Library. Oxford: Update Software; 2004; 1.
Link: www.update-software.com/cochrane
[208] Amenta, F.,
Di Tullio, M. A.Tomassoni, D., The cholinergic approach for the treatment of vascular dementia: evidence from pre-clinical and clinical studies. Clin Exp Hypertens, 2002. 24(7-8): p. 697-713.
Evidenzklasse: IV
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12450245
[209] Erkinjuntti, T., Kurz, A., Small, G. W., Bullock, R., Lilienfeld, S.Damaraju, C. V., An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia. Clin Ther, 2003. 25(6): p. 1765-82.
Evidenzklasse: Ib
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=128 60497
[210] Hacke, W., From CURE to MATCH: ADP receptor antagonists
as the treatment of choice for high-risk atherothrombotic patients. Cerebrovasc Dis, 2002. 13 Suppl 1: p. 22-6.
Evidenzklasse: IV
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=118 03184
[211] A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet, 1996. 348(9038): p. 1329-39.
Evidenzklasse: Ib
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=891 8275
[212] Diener, H. C., Cunha, L., Forbes, C., Sivenius, J., Smets, P.Lowenthal, A., European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J
Neurol Sci, 1996. 143(1-2): p. 1-13.
Evidenzklasse: Ib
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=898 1292
[213] Gorelick, P. B., Richardson, D., Kelly, M., Ruland, S., Hung, E., Harris, Y., Kittner, S.Leurgans, S., Aspirin and ticlopidine for prevention of recurrent stroke in black patients: a randomized trial. Jama, 2003. 289(22): p. 2947-57.
Evidenzklasse: Ib
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=127 99402
[214] Nyth, A. L. and Gottfries, C. G., The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. A Nordic multicentre study. Br J Psychiatry, 1990. 157: p.
894-901.
Evidenzklasse: Ib
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=170 5151
[215] Nyth, A.
L., Gottfries, C. G., Lyby, K., Smedegaard-Andersen, L., Gylding-Sabroe, J., Kristensen, M., Refsum, H. E., Ofsti, E., Eriksson, S.Syversen, S., A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia. Acta Psychiatr Scand, 1992. 86(2): p. 138-45.
Evidenzklasse: Ib
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=152 9737
[216] Petracca, G. M., Chemerinski, E.Starkstein, S. E., A double-blind, placebo-controlled study of fluoxetine in depressed patients with Alzheimer's disease. Int Psychogeriatr, 2001. 13(2):
p. 233-40.
Evidenzklasse: Ib
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=114 95397
[217]
Tariot, P. N., Erb, R., Podgorski, C. A., Cox, C., Patel, S., Jakimovich, L.Irvine, C., Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry, 1998. 155(1): p. 54-61.
Evidenzklasse: Ib
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=943
3339
[218] Gutzmann, H., Kuhl, K. P., Kanowski, S.Khan-Boluki, J., Measuring the efficacy of psychopharmacological treatment of psychomotoric restlessness in dementia: clinical evaluation of tiapride. Pharmacopsychiatry, 1997. 30(1): p. 6-11.
Evidenzklasse: Ib
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=906 5963
[219] Allain, H., Dautzenberg, P. H., Maurer, K., Schuck, S.,
Bonhomme, D.Gerard, D., Double blind study of tiapride versus haloperidol and placebo in agitation and aggressiveness in elderly patients with cognitive impairment. Psychopharmacology (Berl), 2000. 148(4): p. 361-6.
Evidenzklasse: Ib
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=109
28308
[220] Nicholson, P. W., Leeman, A. L., O'Neill, C. J., Dobbs, S. M., Deshmukh, A. A., Denham, M. J., Royston, J. P.Dobbs, R. J., Pressure sores: effect of Parkinson's disease and cognitive function on spontaneous movement in bed. Age Ageing, 1988. 17(2): p. 111-5.
Evidenzklasse: III
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=336 9336
[221] Medizinisches Wissensnetzwerk evidence.de der Universität Witten/Herdecke.
Leitlinie Dekubitusprävention. Version 11/2001. www.evidence.de
[222] Hesdorffer, D. C., Hauser, W. A., Annegers, J. F., Kokmen, E.Rocca, W. A., Dementia and
adult-onset unprovoked seizures. Neurology, 1996. 46(3): p. 727-30.
Evidenzklasse: III
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=861 8673
[223] Ueki, A., Shinjo, H., Shimode, H., Nakajima, T.Morita, Y., Factors associated with mortality in patients with early-onset Alzheimer's disease: a five-year longitudinal study. Int J Geriatr Psychiatry, 2001. 16(8): p. 810-5.
Evidenzklasse: III
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=115 36348
[224] Wada, H., Nakajoh, K., Satoh-Nakagawa, T., Suzuki, T., Ohrui, T., Arai, H.Sasaki, H., Risk factors of aspiration pneumonia in Alzheimer's disease patients. Gerontology, 2001. 47(5): p. 271-6.
Evidenzklasse: III
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=114 90146
[225] Beard, C. M.,
Kokmen, E., Sigler, C., Smith, G. E., Petterson, T.O'Brien, P. C., Cause of death in Alzheimer's disease. Ann Epidemiol, 1996. 6(3): p. 195-200.
Evidenzklasse: III
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=882 7154
[226] Wolfson, C., Wolfson, D. B., Asgharian, M., M'Lan, C. E., Ostbye, T., Rockwood, K.Hogan, D. B., A reevaluation of the duration of survival after the onset of dementia. N Engl J Med, 2001. 344(15): p. 1111-6.
Evidenzklasse: III
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11297701
[227] Zakzanis, K. K., Graham, S. J.Campbell, Z., A meta-analysis of structural and functional brain imaging in dementia of the Alzheimer's type: a neuroimaging profile. Neuropsychol Rev, 2003. 13(1): p. 1-18.
Evidenzklasse: Ia
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=126 91498
[228] Ballard, C. and
O'Brien, J., Treating behavioural and psychological signs in Alzheimer's disease. Bmj, 1999. 319(7203): p. 138-9.
Evidenzklasse: IV
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=104 06732
[229] Palmer, K., Backman, L., Winblad, B.Fratiglioni, L., Detection of Alzheimer's disease and dementia in the preclinical phase: population based cohort study. Bmj, 2003. 326(7383): p. 245.
Evidenzklasse: III
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=125 60271
[230] Black, S. E., Patterson, C.Feightner, J., Preventing dementia. Can J Neurol Sci, 2001. 28 Suppl 1: p. S56-66.
Evidenzklasse: IV
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11237312
[231] Boustani, M., Peterson, B., Hanson, L., Harris, R.Lohr, K. N., Screening for dementia in
primary care: a summary of the evidence for the u.s. Preventive services task force. Ann Intern Med, 2003. 138(11): p. 927-37.
Evidenzklasse: Ia
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=127 79304
[232] Bridges-Parlet, S., Knopman, D.Steffes, S., Withdrawal of neuroleptic medications from institutionalized dementia patients: Results of a double-blind, baseline-treatment-controlled pilot study. Journal of Geriatric Psychiatry & Neurology, 1997. 10(3): p. 119-126.
Evidenzklasse: Ib
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=932 2135
[233] Erkinjuntti, T., Kurz, A., Gauthier, S., Bullock, R.,
Lilienfeld, S.Damaraju, C. V., Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet, 2002. 359(9314): p. 1283-90.
Evidenzklasse: Ib
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=119
65273
[234] Hallauer, J.F. and Kurz, A., Weißbuch Demenz. Vol. 1. 2002, Stuttgart: Thieme Verlag. 137.
[235] Opie, J., Rosewarne, R.O'Connor, D. W., The efficacy of psychosocial approaches to behaviour disorders in dementia: a systematic
literature review. Aust N Z J Psychiatry, 1999. 33(6): p. 789-99.
Evidenzklasse: Ia
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=106 19204
[236] Cohen-Mansfield, J., Nonpharmacologic interventions for inappropriate behaviors in dementia: a review, summary, and critique. Am J Geriatr Psychiatry, 2001. 9(4): p. 361-81.
Evidenzklasse: IV
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=117
39063
[237] Nagy, Z., Hindley, N. J., Braak, H., Braak, E., Yilmazer-Hanke, D. M., Schultz, C., Barnetson, L., Jobst, K. A., Smith, A. D., Relationship between clinical and radiological diagnostic criteria for Alzheimer's disease and the extent of neuropathology as reflected by 'stages': a prospective study. Dement Geriatr Cogn Disord, 1999. 10(2): p. 109-14.
Evidenzklasse: III
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=100 26384
[238] Commissaris, K.,
Verhey, F. R.Jolles, J., A controlled study into the effects of psychoeducation for patients with cognitive disturbances. J Neuropsychiatry Clin Neurosci, 1996. 8(4): p. 429-35.
Evidenzklasse: IIa
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=911
6480
[239] Ermini-Funfschilling, D. and Meier, D., [Memory training: an important constituent of milieu therapy in senile dementia]. Z Gerontol Geriatr, 1995. 28(3): p. 190-4.
Evidenzklasse: III
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=766 4193
[240] Hofmann, M., Hock, C., Kuhler, A.Muller-Spahn, F., Interactive computer-based cognitive training in patients with Alzheimer's disease. J Psychiatr Res, 1996. 30(6): p. 493-501.
Evidenzklasse: III
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=902 3793
[241] Aldridge, David and Aldridge, Gudrun,
Two epistemologies: Music Therapy and medicine in the treatment of dementia. 1991.
Evidenzklasse: IV
Link: www.musictherapyworld.net
[242] Chung, J.C.C., Lai, C.K.Y., Chung, P.M.B.French, H.P., Snoezelen for dementia (Cochrane
Review), in The Cochrane Library. 2003(3), Update Software: Oxford.
Evidenzklasse: Ia
Link: www.update-software.com/cochrane
[243] Spector, A., Davies, S., Woods, B.Orrell, M., Reality orientation for dementia: a
systematic review of the evidence of effectiveness from randomized controlled trials. Gerontologist, 2000. 40(2): p. 206-12.
Evidenzklasse: Ia
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10820923
[244] Spector, A., Orrell, M., Davies, S.Woods, B., Reality orientation for dementia (Cochrane Review). Cochrane Database Syst Rev, 2003(3).
Evidenzklasse: Ia
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11034699
[245] Spector, A., Orrell, M., Davies, S.Woods, R. T., Reminiscence therapy for dementia (Cochrane Review). Cochrane Database Syst Rev, 2003(3).
Evidenzklasse: Ia
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11034700
[246] Forbes, D. A., Strategies for managing behavioural symptomatology associated with dementia of the Alzheimer type: a systematic overview. Can J Nurs Res, 1998. 30(2): p. 67-86.
Evidenzklasse: Ia
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=980 7289
[247] Schrijnemaekers, V., van Rossum, E., Candel, M., Frederiks, C., Derix, M., Sielhorst, H.van den Brandt, P., Effects of emotion-oriented care on elderly people with cognitive impairment and
behavioral problems. Int J Geriatr Psychiatry, 2002. 17(10): p. 926-37.
Evidenzklasse: Ib
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=123 25052
[248] Grasel, E., Wiltfang, J.Kornhuber, J., Non-drug therapies for dementia: an overview of the current situation with regard to proof of effectiveness. Dement Geriatr Cogn Disord, 2003. 15(3): p. 115-25.
Evidenzklasse: IV
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=125 84426
[249] Neal, M. and Briggs, M., Validation therapy for dementia (Cochrane Review). Cochrane Database Syst Rev, 2003(3): p. CD001394.
Evidenzklasse: Ia
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=107 96644
[250] Proctor, R., Burns, A., Powell, H. S., Tarrier,
N., Faragher, B., Richardson, G., Davies, L.South, B., Behavioural management in nursing and residential homes: a randomised controlled trial. Lancet, 1999. 354(9172): p. 26-9.
Evidenzklasse: Ib
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=104
06361
[251] Bundesministerium für Familie, Senioren, Frauen und Jugend, Vierter Altenbericht zur Lage der älteren Generation in der Bundesrepublik Deutschland: Risiken, Lebensqualität und Versorgung Hochaltriger – unter besonderer Berücksichtigung demenzieller Erkrankungen. 2002.
Link: http://www.bmfsfj.de/Anlage21935/14_8822_Teil_3.pdf
[252] Lancioni, G. E., Cuvo, A. J.O'Reilly, M. F., Snoezelen: an overview of research with people with developmental disabilities and dementia. Disabil Rehabil, 2002. 24(4): p. 175-84.
Evidenzklasse: Ia
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=119 26258
[253] Brodaty, H., Ames, D., Snowdon, J., Woodward, M.,
Kirwan, J., Clarnette, R., Lee, E., Lyons, B.Grossman, F., A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry, 2003. 64(2): p. 134-43.
Evidenzklasse: Ib
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=126
33121
[254] Ballard, C. G., O'Brien, J. T., Reichelt, K.Perry, E. K., Aromatherapy as a safe and effective treatment for the management of agitation in severe dementia: the results of a double-blind, placebo-controlled trial with Melissa. J Clin Psychiatry, 2002. 63(7): p. 553-8.
Evidenzklasse: Ib
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=121 43909
[255] Thorgrimsen, L., Spector, A., Wiles, A.Orrell, M.,
Aroma therapy for dementia (Cochrane Review), in Cochrane Library. 2003(3) , Update Software: Oxford.
Evidenzklasse: Ia
Link: www.update-software.com/cochrane
[256] Lonergan, E., Luxenberg, J.Colford, J., Haloperidol for
agitation in dementia (Cochrane Review), in The Cochrane Library. 2003, Update Software: Oxford.
Evidenzklasse: Ia
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12076456
[257] Vollmar HC, Koneczny N, Floer B, Isfort J, Kunstmann W, Butzlaff M. Evidenzbasierte Leitlinien als Instrumente des Wissenstransfers in die Praxis. Die Arbeitsweise des medizinischen Wissensnetzwerks evidence.de. Fortschr Med 2002;120(Originalien IV/2002):125-130.
Evidenzklasse: IV
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12613269&dopt=A bstract
[258] Davis, D.A. and A. Taylor-Vaisey, Translating guidelines into practice. A systematic review of theoretic concepts, practical experience and research evidence in the
adoption of clinical practice guidelines. Cmaj, 1997. 157(4): 408-16.
Evidenzklasse: Ia
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9275952&dopt=Ab stract
[259] Freeman, A.C. and K. Sweeney, Why general practitioners do not implement evidence: qualitative study. Bmj, 2001. 323(7321): 1100-1105.
Evidenzklasse: III
Link: http://bmj.com/cgi/content/abstract/323/7321/1100
[260] Grol, R., Successes and failures in the implementation of evidence-based guidelines for clinical practice. Med Care, 2001. 39(8 Suppl 2): II46-54.
Evidenzklasse: IV
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11583121&dopt=A bstract
[261] Ollenschlaeger, G., H. Kirchner, and M. Fiene, Leitlinien in der praktischen Medizin - scheitern sie an der Umsetzung.
Internist, Der, 2001. 42: 473-83.
Evidenzklasse: IV
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11326730&dopt=A bstract
[262] Vollmar HC, Koneczny N, Floer B, Butzlaff M.
Evidenzbasiertes Wissen im Internet für Ärzte und Patienten
in Jaeckel A: Telemedizinführer Deutschland 2003. Deutsches Medizin Forum: Darmstadt; 2002
[263] Butzlaff M, Koneczny N, Floer B, Vollmar HC, Lange S, Kunstmann W, Köck C.
Hausärzte, Internet und neues Wissen. Nutzung und Effizienzeinschätzung von fortbildungsmedien durch Allgemeinärzte und hausärztlich tätige Internisten.
Med Klin. 2002 Jul 15;97(7):383-388.
Evidenzklasse: Ib
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12168475&dopt=A bstract
[264] Butzlaff M, Floer B, Koneczny N, Vollmar HC, Lange S, Isfort J, Kunstmann W.
www.evidence.de - Netzbasierte
Leitlinien im Praxistest. Beurteilung und Nutzung von evidenzbasierten und netzgestützten Leitlinien durch Allgemeinärzte und hausärztlich tätige Internisten.
Z Arztl Fortbild Qualitatssich. 2002 Feb;96(2):127-33
Evidenzklasse: Ib
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11921609&dopt=A
bstract
[265] Forette, F., Seux, M. L., Staessen, J. A., Thijs, L., Birkenhager, W. H., Babarskiene, M. R., Babeanu, S., Bossini, A., Gil-Extremera, B., Girerd, X., Laks, T., Lilov, E., Moisseyev, V., Tuomilehto, J., Vanhanen, H., Webster, J., Yodfat, Y.Fagard, R., Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe
(Syst-Eur) trial. Lancet, 1998. 352(9137): p. 1347-51.
Evidenzklasse: Ia
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9802273
[266] Gormley, N., Lyons, D.Howard, R., Behavioural management of aggression in dementia: a randomized controlled trial. Age Ageing, 2001. 30(2): p. 141-5.
Evidenzklasse: Ib
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11395344
http://ageing.oupjournals.org/cgi/content/full/30/2/141
http://ageing.oupjournals.org/cgi/content/abstract/30/2/141
[267] Grossberg, G. T., The ABC of Alzheimer's disease: behavioral symptoms and their treatment. Int Psychogeriatr, 2002. 14 Suppl 1: p. 27-49.
Evidenzklasse: IV
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=126
36179
[268] Herrmann, N., Recommendations for the management of behavioral and psychological symptoms of dementia. Can J Neurol Sci, 2001. 28 Suppl 1: p. S96-107.
Evidenzklasse: Ia
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11237317
[269] Hogervorst, E., Williams, J., Budge, M., Riedel, W.Jolles, J., The nature of the effect of female gonadal hormone replacement therapy on cognitive function in post-menopausal women: a meta-analysis. Neuroscience,
2000. 101(3): p. 485-512.
Evidenzklasse: Ia
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11113299
[270] Mulnard, R. A., Cotman,
C. W., Kawas, C., van Dyck, C. H., Sano, M., Doody, R., Koss, E., Pfeiffer, E., Jin, S., Gamst, A., Grundman, M., Thomas, R.Thal, L. J., Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study. Jama, 2000. 283(8): p. 1007-15.
Evidenzklasse: Ib
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10697060
[271] Rovner, B. W., Steele, C. D., Shmuely, Y.Folstein, M. F., A randomized trial of dementia care in nursing homes. J Am Geriatr Soc, 1996. 44(1): p. 7-13.
Evidenzklasse: Ib
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=853 7594
[272] Smith, G. B., Case management guideline: Alzheimer
disease and other dementias. Lippincotts Case Manag, 2002. 7(2): p. 77-84.
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11984271
[273] Vittinghoff, E., Shlipak, M. G., Varosy, P. D., Furberg, C. D., Ireland, C. C., Khan, S. S., Blumenthal, R., Barrett-Connor, E.Hulley, S., Risk factors and secondary prevention in women with heart disease: the Heart and Estrogen/progestin Replacement Study. Ann Intern Med, 2003. 138(2): p. 81-9.
Evidenzklasse: Ib
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=125 29088
[274] Rossouw, J. E., Anderson, G. L., Prentice, R. L., LaCroix, A. Z., Kooperberg, C., Stefanick, M. L., Jackson, R. D., Beresford, S. A., Howard, B. V., Johnson, K. C., Kotchen, J. M.Ockene, J., Risks
and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. Jama, 2002. 288(3): p. 321-33.
Evidenzklasse: Ib
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=121
17397
[275] Schulz, R., O'Brien, A., Czaja, S., Ory, M., Norris, R., Martire, L. M., Belle, S. H., Burgio, L., Gitlin, L., Coon, D., Burns, R., Gallagher-Thompson, D.Stevens, A., Dementia caregiver intervention research: in search of clinical significance. Gerontologist, 2002. 42(5): p. 589-602.
Evidenzklasse: Ia
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12351794
[276] Mittelman, M. S., Ferris, S. H., Shulman, E., Steinberg, G.Levin, B., A family
intervention to delay nursing home placement of patients with Alzheimer disease. A randomized controlled trial. Jama, 1996. 276(21): p. 1725-31.
Evidenzklasse: Ib
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=894 0320
[277] Brodaty, H., Green, A.Koschera, A., Meta-analysis of psychosocial interventions for caregivers of people with dementia. J Am Geriatr Soc, 2003. 51(5): p. 657-64.
Evidenzklasse: Ia
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=127 52841
[278] Marriott, A., Donaldson, C., Tarrier, N.Burns, A., Effectiveness of cognitive-behavioural family intervention in reducing the burden of care in carers of patients with Alzheimer's disease. Br J
Psychiatry, 2000. 176: p. 557-62.
Evidenzklasse: Ib
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=109 74962
[279] Screening for dementia: recommendation and rationale. Ann Intern Med, 2003. 138(11): p. 925-6.
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=127 79303
[280] Haupt, M., Karger, A., Baumgartner, D., Kuminoti, D., Janner, M.Schneider, F., [Improvement of agitation and anxiety in dementia patients after psychoeducative training of their caregivers]. Fortschr Neurol Psychiatr, 2000. 68(5): p. 216-23.
Evidenzklasse: III
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=108 58946
[281] Haupt, M., Siebel, U., Palm, B., Kretschmar, J. H.Janner, M., [Effects of family-centered group therapy with demented patients and their caregivers]. Fortschr Neurol Psychiatr, 2000.
68(11): p. 503-15.
Evidenzklasse: III
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=111 44935
[282] Smith, G. B., Case management guideline: Alzheimer disease and other dementias. Lippincotts Case Manag, 2002. 7(2): p. 77-84.
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11984271
[283] Lloyd-Williams, M. and Payne, S., Can multidisciplinary guidelines improve the palliation of symptoms in the terminal phase of dementia? Int J Palliat Nurs, 2002. 8(8): p. 370-5.
Evidenzklasse: III
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12271257
[284] Kitwood, Tom, Demenz - Der personenzentrierte Ansatz im Umgang mit verwirrten Menschen. Christian Müller. 2000, Bern: Verlag Hans Huber. 221.
[285] Turner, S., Iliffe, S., Downs, M., Bryans, M., Wilcock, J.Austin, T., Decision support software for
dementia diagnosis and management in primary care: relevance and potential. Aging Ment Health, 2003. 7(1): p. 28-33.
Evidenzklasse: III
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=125 54312
[286] Hackam, D. G. and Anand, S. S., Emerging risk factors for atherosclerotic vascular disease: a critical review of the evidence. Jama, 2003. 290(7): p. 932-40.
Evidenzklasse: Ia
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=129
28471
[287] Alzheimer Europe. Handbuch der Betreuung und Pflege von Alzheimer-Patienten, ed. A. Kurz. Vol. 1. 1999, Stuttgart: Thieme Verlag. 128.
[288] Verghese, J., Lipton, R. B., Hall, C. B., Kuslansky, G., Katz, M. J.Buschke, H., Abnormality
of gait as a predictor of non-Alzheimer's dementia. N Engl J Med, 2002. 347(22): p. 1761-8.
Evidenzklasse: III
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=124 56852
[289] Smith, D. J. and Yukhnevich, S., Adverse reactions to rivastigmine in three cases of dementia. Aust N Z J Psychiatry, 2001. 35(5): p. 694-5.
Evidenzklasse: IV
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=115
51292
[290] Schaie, K. W., The Seattle Longitudinal Study: a thirty-five-year inquiry of adult intellectual development. Z Gerontol, 1993. 26(3): p. 129-37.
Evidenzklasse: III
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=833 7905
[291] Qizilbash N, Whitehead A, Higgins J, Wilcock G, Schneider L, Farlow M. Cholinesterase inhibition for Alzheimer disease: a meta-analysis of the tacrine trials. Dementia Trialists' Collaboration.
JAMA. 1998; 280: 20: 1777-82
Evidenzklasse: Ia
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9842955
[292] Qizilbash, N., Birks,
J., Lopez Arrieta, J., Lewington, S. S., Szeto, Tacrine for Alzheimer's disease (Cochrane Review), in Cochrane Library. 2003, 3, Update Software: Oxford. (withdrawn)
Evidenzklasse: Ia
Link: www.update-software.com/cochrane
[293] Deutsche Gesellschaft für Neurologie (DGN), Diagnose und Therapie der Alzheimer-Demenz (AD)und der Demenz mit Lewy-Körperchen (DLB). 2002.
Link: http://www.uni-duesseldorf.de/AWMF/ll/neur-029.htm
[294] Deutsche Gesellschaft für Neurologie (DGN), Vaskuläre Demenz. 2002.
Link: http://www.uni-duesseldorf.de/AWMF/ll/neur-038.htm
[295] Arzneimittelkommission der deutschen Ärzteschaft (AKDÄ), Primär- und
Sekundärprävention des ischämischen Insults. Arzneiverodnung in der Praxis (AVP). Therapieempfehlungen der Arzneimittelkommission der deutschen Ärzteschaft, Vol. 1. 1999.
Link: http://www.akdae.de/35/10Hefte/96_IschaemischenInsults_1999_1Auflage.pdf
[296] Tabet, N., Birks, J.Grimley Evans, J., Vitamin E for Alzheimer's disease (Cochrane Review). Cochrane Database Syst Rev, 2003. 3.
Evidenzklasse: Ia
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11034775
[297] Luchsinger, J. A., Tang, M. X., Shea, S.Mayeux, R., Antioxidant vitamin intake and risk of Alzheimer disease. Arch Neurol, 2003. 60(2): p. 203-8.
Evidenzklasse: III
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=125 80704
[298] Tabet, N. and Feldman, H., Indomethacin for the treatment of Alzheimer's disease patients (Cochrane Review), Cochrane Database Syst Rev, 2003. 3.
Evidenzklasse: Ia
Link: www.update-software.com/cochrane
[299] Tabet, N. and Feldmand, H., Ibuprofen for Alzheimer's disease (Cochrane Review), Cochrane Database Syst Rev, 2003. 3.
Evidenzklasse: Ia
Link: www.update-software.com/cochrane
[300] Szatmari, Sz. and P.J., Whitehouse, Vinpocetine for cognitive impairment and dementia (Cochrane Review), Cochrane Database Syst Rev, 2003. 3.
Evidenzklasse: Ia
Link: www.update-software.com/cochrane
[301] Martin, H., Slyk, M. P., Deymann, S.Cornacchione, M. J., Safety profile assessment of risperidone and olanzapine in long-term care patients with dementia. J Am Med Dir Assoc, 2003. 4(4): p. 183-8.
Evidenzklasse: III
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=128 37138
[302] Fontaine, C. S.,
Hynan, L. S., Koch, K., Martin-Cook, K., Svetlik, D.Weiner, M. F., A double-blind comparison of olanzapine versus risperidone in the acute treatment of dementia-related behavioral disturbances in extended care facilities. J Clin Psychiatry, 2003. 64(6): p. 726-30.
Evidenzklasse: Ib
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=128
23090
[303] Sivenius, J., Cunha, L., Diener, H. C., Forbes, C., Laakso, M., Lowenthal, A., Smets, P.Riekkinen, P., Sr., Second European Stroke Prevention Study: antiplatelet therapy is effective regardless of age. ESPS2 Working Group. Acta Neurol Scand, 1999. 99(1): p. 54-60.
Evidenzklasse: Ib
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=992 5239
[304] Undas, A., Undas, R., Musial, J.Szczeklik, A., A low dose
of aspirin (75 mg/day) lowers thrombin generation to a similar extent as a high dose of aspirin (300 mg/day). Blood Coagul Fibrinolysis, 2000. 11(3): p. 231-4.
Evidenzklasse: Ib
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=108
70801
[305] Tackenberg, P. and Zegelin-Abt, A., Demenz und Pflege. Eine interdisziplinäre Betrachtung. Vol. 1. 2000, Frankfurt am Main: Mabuse Verlag. 323.
[306] Maciejewski, B., Sowinski, C., Besselmann, K.Rückert, W., Qualitätshanbuch Leben mit
Demenz. Vol. 1. 2001, Köln: Kuratorium Deutsche Altershilfe. 21.
[307] Wesnes K, Anand R, Lorscheid T. Potential of moclobemide to improve cerebral insufficiency identified using a scopolamine model of aging and dementia. Acta Psychiatr Scand Suppl. 1990;360:71-2.
Evidenzklasse: III
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=224 8080
[308] Womack KB, Heilman KM. Tolterodine and memory: dry but
forgetful. Arch Neurol. 2003 May;60(5):771-3. Case Report
Evidenzklasse: IV
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=127 56144
[309] MNG Dukes, JK Aronson (Editor). Meyler's Side Effects of Drugs: The Encyclopedia of Drug Adverse Reactions (Meyler's Side Effects of Drugs), 14th Edition, 2000.
[310] Maxwell CJ, Hogan DB, Ebly EM. Calcium-channel blockers and cognitive function
in elderly people: results from the Canadian Study of Health and Aging. CMAJ. 1999 Sep 7;161(5):501-6. Erratum in: CMAJ 1999 Nov 30;161(11):1396.
Evidenzklasse: Ib
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=104 97605
[311] Bowen JD, Larson EB. Drug-induced cognitive impairment. Defining the problem and finding solutions. Drugs Aging. 1993 Jul-Aug;3(4):349-57.
Evidenzklasse: IV
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=836 9594
[312] Keller S, Frishman WH, Epstein J. Neuropsychiatric manifestations of cardiovascular drug therapy. Heart Dis. 1999 Sep-Oct;1(4):241-54.
Evidenzklasse: IV
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=117 20631
[313] T Vial, J Descotes: Clinical Toxicity of the interferons. Drug Safety 1994; 10: 115 – 150
Evidenzklasse: IV
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=751 6663
[314] Moulignier A; Allo S; Zittoun R; Gout O : Interferon- -2b: Chorea and frontal subcortical dementia in an elderly patient: case report . Reactions, 2002, vol. 1, no 903, pp8—8 (1)
Evidenzklasse: IV
[315] MN Dohn, WGG Weinberg, RA Torres, SE Follansbee, PT Caldwell et al Oral
Atovaquone compared with intravenous pentamidine for pneumocystis carinii pneumonianin patients with AIDS. Ann Intern Med 1994; 121: 174-180
Evidenzklasse: Ib
Link:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=788 0228
[316] Bernstein AL, Werlin A. Pseudodementia associated with use of ibuprofen. Ann Pharmacother. 2003 Jan;37(1):80-2.).
Evidenzklasse: IV
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=125
03939
[317] McShane R; Keene J; Gedling K;Fairburn C; Jacoby R; et al. Antipsychotics may accelerate cognitive decline in dementia. Reactions, 1997, vol. 1, no. 636, pp. 4-4(1)
Evidenzklasse: IV
[318] Welch JB: Antipsychotics: Dementia following neuroleptic malignant syndrome in an elderly patient: case report, Reactions, 1994, vol. 1, no. 483, pp. 5-5(1)
Evidenzklasse: IV
[319] Allain H, Tessier C, Bentue-Ferrer D, Tarral A, Le Breton S, Gandon M, Bouhours P.
Effects of risperidone on psychometric and cognitive functions in healthy elderly
volunteers. Psychopharmacology (Berl). 2003 Feb;165(4):419-29. Epub 2002 Nov 30.
Evidenzklasse: IV
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=124
59926
[320] Martin H, Slyk MP, Deymann S, Cornacchione MJ. Safety profile assessment of
risperidone and olanzapine in long-term care patients with dementia.
J Am Med Dir Assoc. 2003 Jul-Aug;4(4):183-8.
Evidenzklasse: III
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=128 37138
[321] Chakraborty D, Agarwal CS, Rohatagi R. A case of subacute onset
dementia due to sertraline. J Assoc Physicians India. 2003
Mar;51:323-4.
Evidenzklasse: IV
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=128
39368
[322] Bouman WP; Pinner G; Johnson H: Lamotrigine: Cognitive
impairment in an elderly patient: case report. Reactions, 1997, vol. 1, no. 652, pp. 10-10(1)
Evidenzklasse: IV
[323] Ubogu E; Reed D; Sagar S; Lerner A; Maddux B; et al.: Ketamine: First report of ataxia and exacerbation of dementia: case Report; Reactions, 2002, vol. 1, no. 894, pp. 8-9(2)
Evidenzklasse: IV
[324] King DS; Jones DW; Wofford MR; Harkins K; Harrell TK; et al: Atorvastatin: First report of cognitive impairment in an elderly patient:
case report, Reactions, 2001, vol. 1, no. 849, pp. 7-7(1)
Evidenzklasse: IV
[325] Schwartzenberg GWST; Trope GE: Dorzolamide: Anorexia,
depression and dementia in an elderly patient following ophthalmic administration: case report , Reactions, 1999, vol. 1, no. 771, pp. 8-8(1)
Evidenzklasse: IV
[326] Green HJ; Pakenham KI; Headley BC; Yaxley J; Nicol DL; et al. Androgen ablation therapy may cause cognitive impairment Reactions, 2002, vol. 1, no. 923, pp. 5-5(1)
Evidenzklasse: IV
[327 ] Belanoff JK, Gross K, Yager A, Schatzberg AF. Corticosteroids and cognition. J Psychiatr
Res. 2001 May-Jun;35(3):127-45.
Evidenzklasse: IV
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=114 61709
[328] Kendel K; Kabiri R; Schaffer S: Bismuth subgallate:
Encephalopathy and dementia: case report. Reactions, 1993, vol. 1, no. 458, pp. 5-5(1)
Evidenzklasse: IV
[329] Rivastigmine: First report of exacerbation of dementia in elderly patients. 3 case reports. Reactions
2002, Vol.1, no. 888, pp 11-11
Evidenzklasse: IV
[330] Simon, C and Stille, W, Antibiotika-Therapie in Klinik und Praxis. Vol. 10. 2000: Schattauer, F.K. 720.
Neu in der Version 5/2005:
[331] Schulz, R. and S.R. Beach, Caregiving as a risk factor for mortality: the Caregiver Health Effects Study. Jama, 1999. 282(23): p. 2215-9.
Evidenzklasse: III
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=106
05972
[332] DGGPP: Empfehlungen zur Therapie dementieller Erkrankungen. 2004.
Evidenzklasse: nicht bewertet
Link: http://www.dggpp.de/download/publikationen/DGGPP_EmpfehlungenZurTherapieDementiellerErkrankun genMaerz2004.pdf
[333] Weibler-Villalobos, U., Ernährungsstörungen bei Demenz - Sondenernährung und alternative Versorgungskonzepte. Zeitschrift
für Allgemeinmedizin, 2005. 81: p. 71-76.
Evidenzklasse: IV
Link:
[334] Whitmer, R.A., et al., Midlife cardiovascular risk factors and risk of dementia in late life. Neurology, 2005. 64(2): p. 277-81.
Evidenzklasse: III Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=156 68425
[335] Langa, K.M., N.L. Foster, and E.B. Larson, Mixed dementia: emerging concepts and therapeutic implications.
Jama, 2004. 292(23): p. 2901-8.
Evidenzklasse: Ia Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=155 98922
[336] NICE: Appraisal Consultation Document: Alzheimer's disease - donepezil, rivastigmine, galantamine and memantine (review). 2005, National Institute of Clinical Excellence (NICE).
Evidenzklasse: nicht bewertet Link: http://www.nice.org.uk/page.aspx?o=245912
[337] Schulz, R. and L.M. Martire, Family caregiving of persons with dementia: prevalence, health effects, and support strategies. Am J Geriatr Psychiatry, 2004. 12(3): p. 240-9.
Evidenzklasse: IV Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=151 26224
[338] Yaffe, K., et al., Patient and caregiver characteristics and nursing home placement in patients with dementia. Jama, 2002. 287(16): p. 2090-7.
Evidenzklasse: III Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=119
66383
[339] AHRQ: Pharmacological treatment of dementia. Summary. Number 97, in Evidence Report/Technology Assessement, 2004.
Evidenzklasse: nicht bewertet Link: http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=hstat1.chapter.117422
[340] ÄZQ, Leitlinien-Clearingbericht "Demenz". ÄZQ Schriftenreihe Band 20, 2005, Berlin: Ärztliches Zentrum für Qualität in der Medizin (Gemeinsame Einrichtung
von BÄK und KBV). 201.
Evidenzklasse: nicht bewertet Link: http://www.leitlinien.de/clearingverfahren/clearingberichte/demenz/09demenz/view
[341] Biernat, K., et al., Primary care
residents self assessment skills in dementia. Adv Health Sci Educ Theory Pract, 2003. 8(2): p. 105-10.
Evidenzklasse: III Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=129 13369
[342] Waldorff, F.B., et al., Implementation of a clinical dementia guideline. A controlled study on the effect of a multifaceted strategy. Scand J Prim Health Care, 2003. 21(3): p. 142-7.
Evidenzklasse: III Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=145 31504
[343] Stoppe, G., O. Pirk, and M. Haupt, [Treatment of Alzheimer's disease utilising the best available evidence-based medicine -- utopia?]. Gesundheitswesen, 2005. 67(1): p. 20-6.
Evidenzklasse: IV
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=156
72302
[344] Honig, L.S., et al., Stroke and the risk of Alzheimer disease. Arch Neurol, 2003. 60(12): p. 1707-12.
Evidenzklasse: III
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=146 76044
[345] Schwabe, U., Antidementiva, in Arzneiverordnungsreport 2004, U. Schwabe and D. Paffrath, Editors. 2004, Springer: Berlin. p. 281-299.
Evidenzklasse: nicht bewertet
[346] Larson, E.B., et al., Survival after initial diagnosis of Alzheimer disease. Ann Intern Med, 2004. 140(7): p. 501-9.
Evidenzklasse: III Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=150
68977
[347] Tariot, P.N., et al., Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. Jama, 2004. 291(3): p. 317-24.
Evidenzklasse: Ib
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=147 34594
[348] Gill, S.S., et al., Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study. Bmj, 2005. 330(7489): p. 445.
Evidenzklasse: III
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=156 68211
[349] Whitehead, A., et al., Donepezil for the symptomatic
treatment of patients with mild to moderate Alzheimer's disease: a meta-analysis of individual patient data from randomised controlled trials. Int J Geriatr Psychiatry, 2004. 19(7): p. 624-33.
Evidenzklasse: Ia
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=152
54918
[350] Wynn, Z.J. and J.L. Cummings, Cholinesterase inhibitor therapies and neuropsychiatric manifestations of Alzheimer's disease. Dement Geriatr Cogn Disord, 2004. 17(1-2): p. 100-8.
Evidenzklasse: IV
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=145 64129
[351] N.N., Alzheimer-Mittel Donepezil (Aricept) ohne relevanten Nutzen. Arznei-Telegramm, 2004. 35(7): p. 67-68.
Evidenzklasse: nicht bewertet
Link: www.arzneitelegramm.de
[352] FDA, FDA Issues Public Health Advisory for Antipsychotic Drugs used for Treatment of Behavioral Disorders in Elderly Patients. 2005.
Evidenzklasse: nicht bewertet
Link: http://www.fda.gov/bbs/topics/ANSWERS/2005/ANS01350.html
[353] Raskind, M.A., et al., The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial. Arch Neurol, 2004. 61(2): p. 252-6.
Evidenzklasse: Ib
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=149 67774
[354] Sandholzer, H., et al., [STEP--standardized assessment
of elderly people in primary care]. Dtsch Med Wochenschr, 2004. 129 Suppl 4: p. S183-226.
Evidenzklasse: nicht bewertet
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=155 92957
[355] Sink, K.M., K.F. Holden, and K. Yaffe, Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. Jama, 2005. 293(5): p. 596-608.
Evidenzklasse: Ia
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=156
87315
[356] Lee, P.E., et al., Atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: systematic review. Bmj, 2004. 329(7457): p. 75.
Evidenzklasse: Ia
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=151 94601
[357] Herrmann, N., M. Mamdani, and K.L. Lanctot, Atypical antipsychotics and risk of cerebrovascular accidents. Am J Psychiatry, 2004. 161(6): p. 1113-5.
Evidenzklasse: III
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=151 69702
[358] Jüptner, M. and M. Gastpar, Todesfälle unter Risperidon
und Olanzapin - was nun? Behandlung psychotischer Symptome bei Demenzpatienten. Psychoneuro, 2004. 30(6): p. 314-316.
Evidenzklasse: IV
Link: http://www.thieme-connect.com/ejournals/toc/psychoneuro
[359]
Brauner, D.J., J.C. Muir, and G.A. Sachs, Treating nondementia illnesses in patients with dementia. Jama, 2000. 283(24): p. 3230-5.
Evidenzklasse: IV
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=108 66871
[360] Vollmar, H.C., et al., Update Demenz-Leitlinie: Ein aufwändiger Prozess. Zeitschrift für Allgemeinmedizin, 2004. 80(9): p. 381 (V13).
Evidenzklasse: IV
Link: http://www.thieme-connect.com/ejournals/toc/zfa
[361] Kaduszkiewicz, H., et al., [Doubtful evidence for the use of the cholinesterase inhibitor donepezil in patients with dementia - a systematic review.]. Fortschr Neurol Psychiatr, 2004. 72(10): p. 557-63.
Evidenzklasse: Ia
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=154 72779
[362] Courtney, C., et al., Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet, 2004. 363(9427): p. 2105-15.
Evidenzklasse: Ib
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=152 20031
[363] Holmes, C., et
al., AD2000: design and conclusions. Lancet, 2004. 364(9441): p. 1213-4; author reply 1216-7.
Evidenzklasse: IV
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=154 64172
[364] Schneider, L.S., AD2000: donepezil in Alzheimer's disease. Lancet, 2004. 363(9427): p. 2100-1.
Evidenzklasse: IV
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=152
20027
[365] Lanctot, K.L., et al., Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. Cmaj, 2003. 169(6): p. 557-64.
Evidenzklasse: Ia
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=129 75222
[366] Etminan, M., S. Gill, and A. Samii, Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies. Bmj, 2003.
327(7407): p. 128.
Evidenzklasse: Ia
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=128 69452
[367] Forette, F., Anand, R.Gharabawi, G., A phase II study in patients with Alzheimer's disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon). Eur J Neurol, 1999. 6(4): p. 423-9.
Evidenzklasse: Ib
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=103
62894
[368] Potkin, S. G., Anand, R., Fleming, K., Alva, G., Keator, D., Carreon, D., Messina, J., Wu, J. C., Hartman, R.Fallon, J. H., Brain metabolic and clinical effects of rivastigmine in Alzheimer's disease. Int J Neuropsychopharmacol, 2001. 4(3): p. 223-30.
Evidenzklasse: Ib
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=116 02028
[369] Rockwood, K., Mintzer, J., Truyen, L., Wessel,
T.Wilkinson, D., Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial. J Neurol Neurosurg Psychiatry, 2001. 71(5): p. 589-95.
Evidenzklasse: Ib
Link:http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids
=11606667
[370] Holmes, C., Wilkinson, D., Dean, C., Vethanayagam, S., Olivieri, S., Langley, A., Pandita-Gunawardena, N. D., Hogg, F., Clare, C.Damms, J., The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology, 2004. 63(2): p. 214-9.
Evidenzklasse: Ib
Link:http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids =15277611
[371] Wimo, A., Winblad, B., Engedal, K., Soininen, H.,
Verhey, F., Waldemar, G., Wetterholm, A. L., Mastey, V., Haglund, A., Zhang, R., Miceli, R., Chin, W.Subbiah, P., An economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a 1-year, double-blind, randomized trial. Dement Geriatr Cogn Disord, 2003. 15(1): p. 44-54.
Evidenzklasse: Ib
Link:http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids =12457078
[372] Wallin, A. K., Gustafson, L., Sjogren, M., Wattmo, C.Minthon, L., Five-Year Outcome of Cholinergic Treatment of Alzheimer's Disease: Early Response Predicts Prolonged Time until Nursing Home
Placement, but Does Not Alter Life Expectancy. Dement Geriatr Cogn Disord, 2004. 18(2): p. 197-206.
Evidenzklasse: Ib
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=152 11076
[373] Rogers, S. L. and Friedhoff, L. T., The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US Multicentre, Randomized, Double-Blind, Placebo- Controlled Trial. The Donepezil Study Group. Dementia, 1996. 7(6): p. 293-303.
Evidenzklasse: Ib
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8915035
[374] Rogers, S. L., Doody, R. S., Mohs, R. C.Friedhoff, L. T., Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group.
Arch Intern Med, 1998. 158(9): p. 1021-31.
Evidenzklasse: Ib
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9588436
[375]
Greenberg, S. M., Tennis, M. K., Brown, L. B., Gomez-Isla, T., Hayden, D. L., Schoenfeld, D. A., Walsh, K. L., Corwin, C., Daffner, K. R., Friedman, P., Meadows, M. E., Sperling, R. A.Growdon, J. H., Donepezil therapy in clinical practice: a randomized crossover study. Arch Neurol, 2000. 57(1): p. 94-9.
Evidenzklasse: Ib
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=106 34454
[376] Agid, Y., Dubois, B., Anand, S. S.Gharabawi, G., Efficacy and tolerability of rivastigmine in patients with dementia of the Alzheimer type. Current Therapeutics Research, 1998. 59(12): p. 837-845.
Evidenzklasse: Ib
[377] Warner, James, Butler, RobArya, P., Dementia, in Clinical Evidence, F. Godlee, Editor. 2004, BMJ Publishing Group Limited: London. Evidenzklasse: Ia Link: www.clinicalevidence.com
[378] Anttila, T., Helkala, E. L., Viitanen, M., Kareholt, I., Fratiglioni, L., Winblad, B., Soininen, H., Tuomilehto, J., Nissinen, A.Kivipelto, M., Alcohol drinking in middle age and subsequent risk of mild cognitive impairment and dementia in old age: a prospective population based study. Bmj, 2004. 329(7465): p. 539.
Evidenzklasse: III
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=153 04383
[379] Bowers, J., Jorm, A. F., Henderson, S.Harris, P.,
General practitioners' reported knowledge about depression and dementia in elderly patients. Aust N Z J Psychiatry, 1992. 26(2): p. 168-74.
Evidenzklasse: III
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=164 2607
[380] Brodaty, H., Clarke, J., Ganguli, M., Grek, A., Jorm, A. F., Khachaturian, Z.Scherr, P., Screening for cognitive impairment in general practice: toward a consensus. Alzheimer Dis Assoc Disord, 1998. 12(1): p. 1-13.
Evidenzklasse: IV
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=953 9404
[381] Brodaty, H., Griffin, D.Hadzi-Pavlovic, D., A survey of dementia carers: doctors' communications, problem behaviours and institutional care. Aust N Z J Psychiatry, 1990. 24(3): p. 362-70.
Evidenzklasse: III
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=224 1720
[382] Cooper, B.,
Bickel, H.Schaufele, M., [Dementia diseases and minor cognitive impairments in elderly patients in general practice. Results of a cross-sectional study]. Nervenarzt, 1992. 63(9): p. 551-60.
Evidenzklasse: III
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=140
7226
[383] Cuijpers, P., Hosman, C. M.Munnichs, J. M., Change mechanisms of support groups for caregivers of dementia patients. Int Psychogeriatr, 1996. 8(4): p. 575-87.
Evidenzklasse: III
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=914 7171
[384] Dwolatzky, T. and Clarfield, A. M., Assessement of dementia in primary care setting. Expert Review of Neurotherapeutics, 2004. 4(2): p. 317-325.
Evidenzklasse: IV
[385] Eefsting, J. A., Boersma, F., Van den Brink, W.Van Tilburg, W., Differences in prevalence of dementia based on community survey and general practitioner recognition. Psychol Med, 1996. 26(6): p. 1223-30.
Evidenzklasse: III
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=893 1168
[386] Iliffe, S., Mitchley, S., Gould, M.Haines, A., Evaluation of the use of brief screening instruments for dementia, depression and problem drinking among elderly people in general practice. Br J Gen
Pract, 1994. 44(388): p. 503-7.
Evidenzklasse: III
Link:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=774 8646
[387] Kaduszkiewicz, H and van den Bussche, H, Die hausärztliche Versorgung von Patienten mit kognitiven Störungen und Demenz. Psychoneuro, 2003. 29(6): p. 275-81.
Evidenzklasse: IV
[388] Mant, A., Eyland, E. A., Pond, D. C., Saunders, N. A.Chancellor, A. H., Recognition of dementia in general practice: comparison of general practitioners'
opinions with assessments using the mini-mental state examination and the Blessed dementia rating scale. Fam Pract, 1988. 5(3): p. 184-8.
Evidenzklasse: III
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=322 4784
[389] Norberg, A., Caring for demented patients. Acta Neurol Scand Suppl, 1996. 165: p. 105-8.
Evidenzklasse: IV
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=874
0996
[390] O'Connor, D. W., Fertig, A., Grande, M. J., Hyde, J. B., Perry, J. R., Roland, M. O., Silverman, J. D.Wraight, S. K., Dementia in general practice: the practical consequences of a more positive approach to diagnosis. Br J Gen Pract, 1993. 43(370): p. 185-8.
Evidenzklasse: III
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=834 7384
[391] Pentzek, M. and Abholz, H.-H., Das Erkennen von Demenzen
in der Hausarztpraxis - eine kritische Übersicht zur Studienlage. NeuroGer, 2004. 1(2): p. 69-76.
Evidenzklasse: IV
[392] Riedel-Heller, S. G., Schork, A., Fromm, N.Angermeyer, M. C., [Dementia patients in general practice--results of a survey]. Z Gerontol Geriatr, 2000. 33(4): p. 300-6.
Evidenzklasse: III
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=110 28282
[393] Rosler, M., Frey, U., Retz-Junginger, P., Supprian,
T.Retz, W., [Overview of standardised diagnostic instruments of dementia]. Fortschr Neurol Psychiatr, 2003. 71(4): p. 187-98.
Evidenzklasse: IV
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=126 77552
[394] Ruof, J., Mittendorf, T., Pirk, O.von der Schulenburg, J. M., Diffusion of innovations: treatment of Alzheimer's disease in Germany. Health Policy, 2002. 60(1): p. 59-66.
Evidenzklasse: III
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=118 79945
[395] Sandholzer, H., Breull, A.Fischer, G. C., [Early diagnosis and early treatment of cognitive disorders: a study of geriatric screening of an unselected patient population in general practice]. Z
Gerontol Geriatr, 1999. 32(3): p. 172-8.
Evidenzklasse: III Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=104 36497
[396] Sperber, S., Kaduszkiewicz, Hvan den Bussche, H, Die hausärztliche Versorgung von Patienten mit kognitiven Störungen und Demenzen: Ergebnisse einer repräsentativen postalischen Befragung. Zeitschrift für Allgemeinmedizin, 2004. 80 (Abstracts).
Evidenzklasse: III
[397] van Hout, H., Vernooij-Dassen, M., Bakker, K., Blom, M.Grol, R.,
General practitioners on dementia: tasks, practices and obstacles. Patient Educ Couns, 2000. 39(2-3): p. 219-25.
Evidenzklasse: III Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=110 40721
[398] Wagner, G. and Abholz, H., Diagnose und Therapiemanagement der Demenz in der Hausarztpraxis. Zeitschrift für Allgemeinmedizin, 2002. 78: p. 239-244.
Evidenzklasse: IV
[399] Waldorff, F. B. and Moller, S., Diagnostic evaluation of dementia in general practice in Denmark.
A national survey. Scand J Prim Health Care, 2001. 19(2): p. 117-21.
Evidenzklasse: III Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=114 82412
[400] Wind, A. W., Schellevis, F. G., Van Staveren, G., Scholten, R. P., Jonker, C.Van Eijk, J. T., Limitations of the Mini-Mental State Examination in diagnosing dementia in general practice. Int J Geriatr Psychiatry, 1997. 12(1): p. 101-8.
Evidenzklasse: III Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=905 0431
[401] Blacker, D., Mild Cognitive Impairment -- No Benefit from Vitamin E, Little from Donepezil. N Engl J Med, 2005.
Evidenzklasse: IV Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=158 29528
[402] Petersen, R. C., Thomas, R. G., Grundman, M., Bennett, D., Doody, R., Ferris, S., Galasko, D., Jin, S., Kaye, J., Levey, A., Pfeiffer, E., Sano, M., van Dyck, C. H.Thal, L. J., Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment. N Engl J Med, 2005. 352(9): p. In print.
Evidenzklasse:...Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=158 29527
[403] Powell, J., Hilfen zur Kommunikation bei Demenz. Türen öffnen zum Menschen mit Demenz. 2002, Köln: Kuratorium
Deutsche Altershilfe. 110.
Evidenzklasse: nicht bewertet
Link: www.kda.de
[404] Salloway, S., Ferris, S., Kluger, A., Goldman, R., Griesing, T., Kumar, D.Richardson,
S., Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial. Neurology, 2004. 63(4): p. 651-7.
Evidenzklasse: Ib
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=153 26237
[405] Thal, L. J., Ferris, S. H., Kirby, L., Block, G. A., Lines, C. R., Yuen, E., Assaid, C., Nessly, M. L., Norman, B. A., Baranak, C. C.Reines, S. A., A Randomized, Double-Blind, Study of Rofecoxib in Patients with Mild Cognitive Impairment. Neuropsychopharmacology, 2005.
Evidenzklasse: Ib Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=157 42005
[406] DGN, Deutsche Gesellschaft für Neurologie , Wallesch,
C-W., Förstl, H., Herholz, K., Lang, C.Schmidtke, K., Diagnose und Therapie der Alzheimer-Demenz (AD) und der Demenz mit Lewy-Körperchen (DLB), in Leitlinien für Diagnostik und Therapie in der Neurologie, H.C. Diener, Editor. 2003, Georg Thieme Verlag: Stuttgart.
Evidenzklasse: nicht bewertet
Link:
http://www.dgn.org/fileadmin/leitl/alzheime.pdf
[407] Morris, M. C., Evans, D. A., Bienias, J. L., Tangney, C. C., Hebert, L. E., Scherr, P. A.Schneider, J. A., Dietary folate and vitamin B12 intake and cognitive decline among community-dwelling older persons. Arch Neurol, 2005. 62(4): p. 641-5.
Evidenzklasse: III
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=158 24266
[408] Klatte, Emily T., Scharre, Douglas W., Nagaraja,
Haikady N., Davis, Rebecca A.Beversdorf, David Q., Combination Therapy of Donepezil and Vitamin E in Alzheimer Disease. Alzheimer Disease & Associated Disorders April/June, 2003. 17(2): p. 113-116.
Evidenzklasse: III
[409] Mulsant, B. H., Gharabawi, G. M., Bossie, C. A., Mao, L., Martinez, R. A., Tune, L. E., Greenspan, A. J., Bastean, J. N.Pollock, B. G.,
Correlates of anticholinergic activity in patients with dementia and psychosis treated with risperidone or olanzapine. J Clin Psychiatry, 2004. 65(12): p. 1708-14. Evidenzklasse: Ib
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=156
41877
[410] Renshaw, J., Scurfield, P., Cloke, L.Orrell, M., General practitioners' views on the early diagnosis of dementia. Br J Gen Pract, 2001. 51(462): p. 37-8.
Evidenzklasse:
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=112 71871
[411] DEGAM and Donner-Banzhoff, N, Professionelles Lernen-ein Leben lang.
Stellungnahme zur ärztlichen Fortbildung. 2001, DEGAM.
Evidenzklasse:
Link:
[412] Burrows, P., Continuing professional development: filling the gap between learning needs and learning experience. Education for Primary Care, 2003. 14: p. 411 - 13.
Evidenzklasse:
Link:
[413] Charlton, R., Continuing professional development (CPD) and training. BMJ Classified,
2001. 18.08.2001: p. 2-3.
Evidenzklasse:
Link:
[414] Davis, D., Evans, M., Jadad, A., Perrier, L., Rath, D., Ryan, D., Sibbald, G., Straus, S., Rappolt, S., Wowk, M.Zwarenstein, M., The case for knowledge translation: shortening the journey from evidence to effect. Bmj, 2003. 327(7405): p. 33-5.
Evidenzklasse:
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=128 42955
[415] Cantillon, P., Irish, B.Sales, D., Using computers for
assessment in medicine. Bmj, 2004. 329(7466): p. 606-9.
Evidenzklasse:
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=153 61445
[416] Cantillon, P. and Jones, R., Does continuing medical education in general practice make a difference? Bmj, 1999. 318(7193): p. 1276-9.
Evidenzklasse:
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10231265
Volltext: http://www.bmj.com/cgi/content/full/318/7193/1276
[417] Karnath, B. M., Das Carlo, M.Holden, M. D., A comparison of faculty-led small group
learning in combination with computer-based instruction versus computer-based instruction alone on identifying simulated pulmonary sounds. Teach Learn Med, 2004. 16(1): p. 23-7.
Evidenzklasse: Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=149
87170
[418] Roex, A. and Degryse, J., A computerized adaptive knowledge test as an assessment tool in general practice: a pilot study. Med Teach, 2004. 26(2): p. 178-83.
Evidenzklasse:
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=152 03528
[419]Baehring, T.U. and Fischer, M. R., Problemorientiertes Lehren und Lernen in der Medizin: Neue technische und didaktische Möglichkeiten durch das WWW. Biomedical Journal, 1998. 52: p. 8-12.
Evidenzklasse: IV
[420] Shaffer, K. and Small, J. E., Joseph E. and Nancy O. Whitley Award winner. Blended learning in medical education: use of an integrated approach with web-based small group modules and didactic instruction for teaching radiologic anatomy. Acad Radiol, 2004. 11(9): p. 1059-70.
Evidenzklasse:
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=153 50588
[421] Singer M, Romero B, Koenig E, Forstl H, Brunner
H.[Nightmares in patients with Alzheimer's disease caused by donepezil]. Nervenarzt. 2005 Jan 4; PMID: 15630600
Evidenzklasse: IV
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15 630600
422.Lopez-Pousa, S., Turon-Estrada, A., Garre-Olmo, J., Pericot-Nierga, I., Lozano-Gallego, M., Vilalta-Franch, M., Hernandez-Ferrandiz, M., Morante-Munoz, V., Isern-Vila, A., Gelada-Batlle, E.Majo-Llopart, J., Differential efficacy of treatment with acetylcholinesterase inhibitors in patients with mild and moderate Alzheimer's disease over a 6-month period. Dement Geriatr Cogn Disord, 2005. 19(4):
p. 189-95.
Evidenzklasse: III
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=156 77866
423.Ballard, C., Margallo-Lana, M., Juszczak, E., Douglas, S., Swann, A., Thomas, A., O'Brien, J., Everratt, A., Sadler, S., Maddison, C., Lee, L., Bannister, C., Elvish, R.Jacoby, R., Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. Bmj, 2005. 330(7496): p. 874.
Evidenzklasse: Ib
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=157 22369
424.Winblad, B., Brodaty, H., Gauthier, S., Morris, J. C., Orgogozo, J. M., Rockwood, K., Schneider, L., Takeda,
M., Tariot, P.Wilkinson, D., Pharmacotherapy of Alzheimer's disease: is there a need to redefine treatment success? Int J Geriatr Psychiatry, 2001. 16(7): p. 653-66.
Evidenzklasse: IV
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=114
66744
425.Arzneimittelkommission der deutschen Ärzteschaft (AKDÄ), Höffler, D., Lasek, R.Berthold, H.K., Demenz. Arzneiverodnung in der Praxis (AVP). Therapieempfehlungen der Arzneimittelkommission der deutschen Ärzteschaft,
Vol. 3. 2004, Köln: Arzneimittelkommission der deutschen Ärzteschaft. 29.
Evidenzklasse: nicht bewertet
Link: www.akadae.de
426.Mayor, S., Regulatory authorities review use of galantamine in mild cognitive impairment. Bmj, 2005. 330(7486):
p. 276.
Evidenzklasse: IV
Link: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=156 95272
427. Kaiser,
T., C. Florack, et al. (2005). "Donepezil bei Patienten mit Alzheimer-Demenz. Die AD2000-Studie." Medizinische Klinik 100(3): 157-60.
Evidenzklasse: IV
Link:
[428] Craig D, Birks J. Rivastigmine for vascular cognitive impairment (Review). In: The Cochrane Library. Oxford: Update Software; 2004; 2.
Evidenzklasse: Ia
Link: www.update-software.com/cochrane
[429] Craig D, Birks J. Galantamine for vascular cognitive impairment (Protocol). In: The Cochrane Library. Oxford: Update Software; 2004; 2.
Evidenzklasse: Ia
Link: www.update-software.com/cochrane
Zum Seitenanfang
| |
